

Table of Contents

O-001. Preliminary results of the Polish clinical trial on extended D2 (D2+) vs. standard D2 lymphadenectomy in gastric cancer patients

Popiela T, Kulig J, Kolodziejczyk P, Sierzega M, Szczepanik A
1st Department of Surgery, Jagiellonian University, Krakow, Poland

O-002. Irinotecan / capecitabine versus cisplatin / capecitabine in advanced adenocarcinoma of the stomach or gastroesophageal junction: Interimsanalysis of a randomized German AIO phase II study

Moehler M¹, Kanzler S¹, Geissler M², Raedle J³, Ebert M⁴, Scherubl h⁵, Flieger D⁶, Seufferlein T⁷, Galle P¹, Hoehler T⁸
¹University of Mainz, Germany, ²University of Freiburg, Germany, ³Saarland University, Homburg, Germany, ⁴University Magdeburg, Germany, ⁵Charité - Campus Benjamin Franklin, Berlin, Germany, ⁶Klinikum Aschaffenburg, Germany, ⁷University Hospital of Ulm, Germany, ⁸Prosper-Hospital Recklinghausen, Germany

O-003. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results

Kang Y¹, Kang W², Shin D³, Chen J⁴, Xiong J⁵, Wang J⁶, Lichinitser M⁷, Salas M⁸, Suarez T⁹, Santamaria J¹⁰
¹Asan Medical Center, Seoul, Republic of Korea, ²Samsung Medical Centre, Ilwon-dong, Republic of Korea, ³Gachon Medical School, Gil Medical Center, Namdong-gu Guwal-dong, Republic of Korea, ⁴Jiangsu Cancer Hospital, Jiangsu, China, ⁵1st Affiliated Hospital of Jiangxi Medical College, Jiangxi, China, ⁶Shanghai Changzheng Hospital, Shanghai, China, ⁷Russian Cancer Research Center, Moscow, Russian Federation, ⁸Hospital Sabogal, Lima, Peru, ⁹Centro Medico Pensiones, Yucatan, Mexico, ¹⁰Instituto Oncologico Nacional, Ancon, Panama

O-004. UGT1A1 promoter polymorphisms and pharmacodynamic/pharmacokinetic relationship in advanced colorectal cancer treated with FOLFIRI regimen

Toffoli G¹, Corona G¹, Cecchin E¹, Masier S¹, Luigi S², Buonadonna A³, Azzarello G⁴, Vincenzo d⁵, Da Corte D⁶, Pasetto L⁷
¹Experimental and Clinical Pharmacology -CRO-National Cancer Institute- Aviano, ²Division of Medical Oncology, Ospedale Civile di Vittorio Veneto (TV), ³Medical Oncology -CRO-National Cancer Institute- Aviano, ⁴Medical Oncology - Ospedale P.F. Calvi -Noale, ⁵Medical Oncology -Ospedale di Gorizia and Monfalcone, ⁶Medical Oncology -Ospedale San Martino, Belluno, ⁷Medical Oncology - Istituto Oncologico Veneto, Padova

O-005. Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal cancer (mCRC): A comparative analysis of N9741 and AVF2107

Grothey A¹, Hedrick E², Mass R², Sakar S², Ramanathan R³, Hurwitz H⁴, Goldberg R⁵, Sargent D¹
¹Mayo Clinic, USA, ²Genentech, USA, ³Genentech, ⁴Genentech, ⁵University of Pittsburgh School of Medicine, Pittsburg, PA, USA, ⁶Duke University Medical Center, Durham, NC, ⁷Univeristy of North Carolina Lineberger Comprehensive Cancer Center, ⁸Mayo Clinic

O-006. Bevacizumab plus IFL improves outcomes of patients with metastatic colorectal cancer independent of baseline risk

Hurwitz H¹, Zurlo A², Irl C², Kabbinavar F³
¹Duke University Medical Center, Durham, USA, ²F. Hoffmann-La Roche Ltd, ³University of California at Los Angeles, USA

O-007. Concurrent infusional 5-fluorouracil and "PROTOCOL SPECIFIC" 3D conformal radiotherapy is effective and safe in combination with "sandwich" gemcitabine in the management of locally advanced pancreatic cancer

Spry N¹, Harvey J², MacLeod C³, Borg M⁴, Ngan S⁵, Millar J⁶, Graham P⁷, Delaney G⁸, Reece W⁹, Goldstein D¹⁰
¹Sir Charles Gairdner Hospital, Nedlands, WA, Australia, ²Princess Alexandra Hospital, Woolloongabba, Queensland, Australia, ³Murray Valley Private Hospital, Wodonga, Victoria, Australia, ⁴Ashford Cancer Centre, Ashford, SA, Australia, ⁵Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia, ⁶The Alfred Hospital, Prahran, Victoria, Australia, ⁷St George Hospital, Kogarah, NSW, Australia, ⁸Liverpool

Hospital, Liverpool, NSW, Australia, ⁹Eli Lilly Australia, Sydney, NSW, Australia, ¹⁰Prince of Wales Hospital, Randwick, NSW, Australia

O-009. Response to neoadjuvant chemotherapy and the pattern of recurrence in locally advanced Barrett's cancer. Analysis from the MUNICON trial.

Lordick F, Ott K, Weber W, Stein H, Sendler A, Herrmann K, Peschel C, Fink U, Schwaiger M, Siewert J
Klinikum rechts der Isar, Technical University of Munich, Germany

O-010. Pattern of lymph node metastasis in patients with squamous cell carcinoma of the thoracic esophagus who underwent 3-field lymphadenectomy

Li H, Xiang J, Zhang Y
Cancer Hospital/Cancer Institute of Fudan University, Shanghai, China

O-011. A phase III trial of sunitinib in GIST patients following failure of imatinib mesylate: Updated trial results

Casali P¹, Garrett C², Blackstein M³, Shah M⁴, Verweij J⁵, McArthur G⁶, Judson I⁷, Li J⁸, Baum C⁸, Demetri G⁹
¹Istituto Nazionale Tumori, Milano, Italy, ²H. Lee Moffitt Cancer Center & Research Institute, ³Mount Sinai Hospital and the University of Toronto, ⁴Ohio State University Comprehensive Cancer Center, ⁵Erasmus University Medical Center, ⁶Peter MacCallum Cancer Centre, ⁷Royal Marsden Hospital, ⁸Pfizer Global Research & Development, ⁹Dana-Farber Cancer Institute and Harvard Medical School

O-012. Early results from a treatment-use trial of sunitinib in patients with advanced GIST following failure of imatinib therapy

Dileo P¹, Morgan J¹, Garrett C², Schutte H³, Hurwitz H⁴, Rosen L⁵, Ruka W⁶, Picus J⁷, Baum C⁸, Demetri G¹
¹Dana-Farber Cancer Institute, Boston, USA, ²Lee Moffitt Cancer Center & Research Institute, Tampa, USA, ³Marien Hospital Düsseldorf, Germany, ⁴Duke University Medical Center, Durham, USA, ⁵Premiere Oncology, Santa Monica, USA, ⁶Cancer Center-Institute, Warsaw, Poland, ⁷Siteman Cancer Center, St. Louis, USA, ⁸Pfizer Global Research & Development La Jolla, USA

O-013. Sunitinib activity in imatinib-resistant GIST patients: Correlation with KIT and PDGFRA mutation status

Corless C¹, Heinrich M¹, Maki R², Antonescu C², Fletcher J³, Fletcher C³, Huang X⁴, Baum C⁴, Demetri G⁵
¹OHSU Cancer Institute, ²Memorial Sloan-Kettering Cancer Center, ³Brigham & Women's Hospital, ⁴Pfizer Global Research and Development, ⁵Dana-Farber Cancer Institute

O-014. A phase III comparison of folfoxiri to folfiri as first-line treatment of metastatic colorectal cancer (mcr).

Masi G¹, Brunetti I², Murr R², Benedetti G³, Evangelista W⁴, Picone V⁵, Chiara S⁶, Merlano M⁷, Vitello S⁸, Falcone A^{1,9}
¹Ospedale Riuniti, Livorno, Italy, ²Ospedale S. Chiara, Pisa, Italy, ³Ospedale Bellaria, Bologna, Italy, ⁴Ospedale S. Giovanni le Molinette, Torino, Italy, ⁵Policlinico Umberto I, Roma, Italy, ⁶IST, Genova, Italy, ⁷Azienda Ospedaliera S. Croce e Carle Cuneo, Italy, ⁸Ospedale S. Elia, Caltanissetta, Italy, ⁹Università degli studi, Pisa, Italy

O-015. Randomized phase III trial of the TTD Group comparing Capecitabine and Oxaliplatin (XELOX) vs. Oxaliplatin and 5-Fluorouracil in continuous infusion (FUFOX) as first line treatment in advanced or metastatic colorectal cancer (CRC).

Taberero J¹, Sastre J², Massuti B³, Chaves M⁴, Carrato A⁵, Queralt B⁶, Reina J⁷, Maurel J⁸, Aranda E⁹, Díaz-Rubio E²
¹Hospital Vall D'Hebron. Barcelona, Spain, ²Hospital Clínico San Carlos, Madrid, Spain, ³Hospital General de Alicante, Alicante, Spain, ⁴Hospital Virgen del Rocío, Sevilla, Spain, ⁵Hospital General de Elche, Alicante, Spain, ⁶Hospital Josep Trueta, Girona, Spain, ⁷Hospital Juan Ramón Jiménez, Huelva, Spain, ⁸Hospital Clinic i Provincial, Barcelona, Spain, ⁹Hospital Reina Sofía, Córdoba, Spain

O-016. OXXEL (oxaliplatin plus Xeloda) vs OXAFAFU (oxaliplatin plus folinic acid-modulated 5-fluorouracil i.v. bolus) every 2 weeks in metastatic colorectal carcinoma (MCC): Preliminary safety and activity analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial.

Comella P¹, Filippelli G², Massidda B³, Putzu C⁴, Natale D⁵, Palmeri S⁶, Maiorino L⁷, Condemi G⁸, Leo S⁹, Gambardella A¹⁰
¹National Tumour Institute, Naples, Italy, ²City Hospital, Paola, ³University Medical School, Cagliari, ⁴University Medical School, Sassari, ⁵City Hospital, Penne, ⁶University Medical School, Palermo, ⁷San

Gennaro Hospital, Naples, ⁸City Hospital, Siderno, ⁹City Hospital, Lecce, ¹⁰Secon University Medical School, Naples

O-017. Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and Capecitabine for mCRC - First BEAT

Rivera F¹, Cunningham D², Michael M³, DiBartolomeo M⁴, Kretschmar A⁵, Berry S⁶, Mazier M⁷, Lutiger B⁸, Van Cutsem E⁹

¹Hospital Marqués de Valdecilla, Santander, Spain, ²Royal Marsden Hospital, Sutton, United Kingdom, ³Peter MacCallum Cancer Institute, East Melbourne, Australia, ⁴Istituto Nazionale Tumori, Milano, Italy, ⁵HELIOS-Klinikum, Berlin, Germany, ⁶Sunnybrook Regional Cancer Centre, Toronto, ON, Canada, ⁷Parexel, Paris, France, ⁸F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁹University Hospital Gasthuisberg, Leuven, Belgium

O-018. Safety and efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE)

Kozloff M¹, Hainsworth J², Badrinath S³, Cohn A⁴, Flynn P⁵, Steis R⁶, Dong W⁷, Suzuki S⁷, Sarkar S⁷, Sugrue M⁷, Grothey A⁸

¹Ingalls Hospital, Harvey, IL and the University of Chicago, IL, ²Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, ³Florida Oncology Associates, Jacksonville, FL, ⁴Rocky Mountain Cancer Center, Denver, CO, ⁵Abbott North Western Hospital, Minneapolis, MN, ⁶Atlanta Cancer Care, Roswell, GA, ⁷Genentech, Inc., South San Francisco, CA, ⁸Mayo Clinic, Rochester, MN

O-019. A phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR). Preliminary results.

Dittrich C¹, Hoehler T², Lordick F³, Seufferlein T⁴, Riemann J⁵, Woell E⁶, Herrmann T⁷, Arnold D⁸, Olchowka K⁹, Schmoll H¹⁰

¹-ACR VIEnna u. ACR-ITR VIEnna, Oncol. KFJ, Austria, ²Johannes-Gutenberg University Hospital Mainz, Germany, ³Klinikum rechts der Isar, Technische Universitaet Muenchen, Germany., ⁴Universitaets-Klinikum, Ulm, Germany, ⁵Klinikum der Stadt Ludwigshafen, Germany, ⁶University Hospital Innsbruck, Austria, ⁷University Hospital Heidelberg, Germany, ⁸Martin-Luther University Hospital, Halle, Germany, ⁹Merck KGaA, Darmstadt, Germany., ¹⁰Martin-Luther University Hospital Halle, Germany

O-020. Importance of histologic tumor response to neoadjuvant chemotherapy in colorectal liver metastases

Rubbia-Brandt L¹, Giostra E², Brezault C⁵, Roth A³, Andres A², Majno P², Soubrane O⁶, Chaussade S⁵, Mentha G², Terris B⁴

¹Unit of Gastrointestinal and Liver Pathology, University Hospital, Geneva, Switzerland, ²Division of Visceral and Transplantation Surgery, University Hospital, Geneva, Switzerland, ³Unit of Oncosurgery, University Hospital, Geneva, Switzerland, ⁴Service d'Anatomie Pathologique, Hôpital Cochin, Paris, France, ⁵Gastroenterology, Hôpital Cochin, Paris, France, ⁶Surgery, Hôpital Cochin, Paris, France

O-021. MRI detects extra-mural vascular invasion and predicts outcome in colorectal cancer

Smith N¹, Norman A², Swift I¹, Brown G²

¹Mayday University Hospital, Croydon, Surrey, UK, ²Royal Marsden Hospital, Sutton, Surrey, UK

O-022. Preliminary results of the MRC CR07 randomised trial comparing routine short course pre-op radiotherapy and selective post-op chemoradiotherapy: the effect of treatment and other factors on local recurrence in resectable rectal cancer

Sebag-Montefiore D, Steele R, Quirke P, Grieve R, Khanna S, Monson J, Holliday A, Thompson L, Stephens R, Griffiths G

NCRI colorectal study group; MRC Clinical Trial Unit, London, UK

O-023. Capecitabine + oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer: Final safety findings from a randomized phase III trial

Schmoll H¹, Tabernero J², Nowacki M³, Maroun J⁴, Price T⁵, Lim R⁶, Van Cutsem E⁷, de Braud F⁸, Haller D⁹

¹Martin Luther University, Halle, Germany, ²Vall d'Hebron University Hospital, Barcelona, Spain, ³Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland, ⁴Ottawa Regional Cancer Centre, Ottawa, ON, Canada, ⁵The Queen Elizabeth Hospital, Adelaide, Australia, ⁶National University Hospital, Singapore, Singapore, ⁷University Hospital Gasthuisberg, Leuven, Belgium, ⁸Istituto Europeo di Oncologia, Milano, Italy, ⁹University of Pennsylvania, Philadelphia, PA, USA

O-024. Tolerability of fluoropyrimidines appears to differ by region

Haller D¹, Cassidy J², Clarke S³, Cunningham D⁴, Van Cutsem E⁵, Hoff P⁶, Rothenberg M⁷, Saltz L⁸, Schmol H⁹, Twelves C¹⁰

¹University of Pennsylvania, USA, ²Glasgow University, Glasgow, UK, ³University of Sydney and Sydney Cancer Centre, Sydney, Australia, ⁴Royal Marsden Hospital, London, UK, ⁵University Hospital Gasthuisberg, Leuven, Belgium, ⁶University of Texas, M. D. Anderson Cancer Center, Houston, TX, USA, ⁷Vanderbilt-Ingram Cancer Center, Nashville, TN, USA, ⁸Memorial Sloan Kettering Cancer Center, New York, NY, USA, ⁹Martin Luther University, Halle, Germany, ¹⁰University of Leeds and Bradford NHS Trust, Bradford, UK

O-025. The role of FDG-PET in the selection of patients with colorectal liver metastases

Ruers T¹, Wiering B¹, Dekker H², Krabbe P³, Oyen W⁴

¹Dept Surgery, Radboud University Nijmegen, Medical Centre, Nijmegen, Netherlands, ²Dept Radiology, Radboud University Nijmegen, Medical Centre, Nijmegen, Netherlands, ³Dept. MTA, Radboud University Nijmegen, Medical Centre, Nijmegen, Netherlands, ⁴Dept .Nuclear medicine, Radboud University Nijmegen, Medical Centre, Nijmegen, Netherlands

O-026. MR enteroclysis in the evaluation of the small bowel neoplasm

Masselli G, Casciani E, Poletti E, Lanciotti S, Bertini L, Gualdi G

Emergency Radiology Department, Roma, Italy

O-027. Panitumumab significantly improves progression-free survival in patients with metastatic colorectal cancer

Van Cutsem E¹, Peeters M², Siena S³, Humblet Y⁴, Hendlisz A⁵, Neyns B⁶, Canon J⁷, Van Laethem J⁸, Maurel J⁹, Richardson G¹⁰

¹University Hospital Gasthuisberg, Leuven, Belgium, ²Ghent University Hospital, Ghent, Belgium, ³Ospedale Niguarda Ca' Granda, Milan, Italy, ⁴St-Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium, ⁵Jules Bordet Institute, Brussels, Belgium, ⁶AZ Vrije Universiteit Brussel, Brussels, Belgium, ⁷Centre Hospitalier Notre Dame et Reine Fabiola, Charleroi, Belgium, ⁸Erasmus University Hospital, Brussels, Belgium, ⁹Hospital Clínic de Barcelona, Barcelona, Spain, ¹⁰Cabrini Hospital, Victoria, Australia

O-028. Sunitinib therapy in patients with metastatic colorectal cancer after failure of standard chemotherapy: results of a phase II trial

Lenz H¹, Marshall J², Rosen L³, Belt R⁴, Hurwitz H⁵, Eckhardt S⁶, Bergsland E⁷, Haller D⁸, Chao R⁹, Saltz L¹⁰

¹University of Southern California, ²Lombardi Cancer Center, ³Cancer Institute Medical Group, ⁴Oncology Hematology of Kansas City US, ⁵Duke University Medical Center, ⁶University of Colorado Cancer Center, ⁷University of California San Francisco, ⁸University of Pennsylvania, ⁹Pfizer Global Research and Development, ¹⁰Memorial Sloan-Kettering

P-001. AFP-L3 improves AFP performance in the follow up for the development of hepatocellular carcinoma in chronic hepatitis patients.

Antonakis P¹, Konstadoulakis M¹, Katakaki A¹, Roayaie S², Schwartz M²

¹Laboratory of Surgical Research, A' Department of Propaedeutic Surgery, University of Athens Medical School, Athens, Greece, ²The Mount Sinai Medical Center, New York, USA

P-002. Intrahepatic pegylated liposomal doxorubicin (pld) in patients with liver malignancies

Granetto C, Fea E, Colantonio I, Di Costanzo G, Garrone O, Gasco M, Ocelli M, Heouaine A, Numico G, Merlano M

Department of Medical Oncology, District Hospital, Cuneo, Italy

P-003. Achyranthes aspera L extract act as antitumour and antioxidant potential against N-nitrosodiethylamine induced hepatocellular carcinoma in rats.

Kartik R¹, Reddy G, Rao C, Unnikrishnan M², Trivedi S³, Pushpangadan P¹

¹National Botanical Research Institute(CSIR), Lucknow, India, ²College of Pharmaceutical Sciences, Manipal, India., ³University of Lucknow, Lucknow, India.

P-004. Treatment of locally advanced and metastatic hepatocellular carcinoma (HCC) with gemcitabine (G) cisplatin (C) combination.

Mahfouf H¹, Djedi H¹, Oukkal M¹, Bentsbak K², Graba A², Bouzid K

¹Department of Medical Oncology, Algiers, Algeria, ²Department of Surgery, Algiers, Algeria

P-005. Carcinogen-metabolizing enzyme activity in the liver: Beneficial effect of the phytotherapeutic compound YHK

Marotta F¹, LeCroix P², Harada M³, Masulair K⁴, Lorenzetti A¹, Sagran P⁴, Fesce E¹

¹Hepto-Gastroenterology Unit, SG Hosp. Milano, Italy, ²alpha-omega TechnoLab, Geneve, Swiss, ³MCH Hospital, Tokio, Japan, ⁴SFJO & Lab, Paris, France

P-006. Isolated liver perfusion for unresectable tumors: correlation between drug pharmacokinetics and hepatic toxicity

Pilati P, Da Pian P, Mocellin S, Forlin M, Corazzina S, Nitti D

University of Padova, Padova, Italy

P-007. Cissampelos pareria extract induced changes in biochemical enzymes and antioxidant status in aflatoxin B1 caused hepatocellular carcinoma bearing rats

Reddy D¹, Kartik R¹, Rao C¹, Unnikrishnan M², Trivedi S³, Palpu P¹, Tuli R¹

¹National Botanical Research Institute (CSIR), Lucknow, India, ²College of Pharmaceutical Sciences, Manipal, India., ³University of Lucknow, Lucknow, India.

P-008. Impact of lymphangiogenesis in colorectal liver metastases

Schoppmann S, Fenzl A, Tamandl D, Bodingbauer M, Schindl M, Puhalla H, Grünberger B, Teleky B, Grünberger T, **Längle F**

Department of Surgery, Medical University of Vienna, Vienna, Austria

P-009. Chromosome 18 transfer into human pancreatic cancer cells suppress metastatic activity

Dajbog E^{1,2,3}, Lefter L^{1,2,3}, Scripcariu V^{1,2}, Dragomir C^{1,2}, Horii A³

¹Third Surgical Unit, Iasi, Romania, ²Centre of Research in Surgical Oncology, "St. Spiridon" University Hospital, University of Medicine and Pharmacy, Iasi, Romania, ³Department of Molecular Pathology, Tohoku University School of Medicine, Sendai, Japan

P-010. Antitumor efficacy of panitumumab alone or with gemcitabine against human pancreatic carcinoma xenografts

Freeman D¹, Bush T¹, Ogbagarbriel S¹, Ziegler B¹, Belmontes B¹, Van G², Johnson C², Radinsky R¹

¹Amgen- Oncology Research, Thousand Oaks, CA, USA, ²Amgen- Pathology, Thousand Oaks, CA, USA

P-011. Phase I trial of capecitabine and gemcitabine with radiotherapy in locally advanced pancreatic cancer

Leong T¹, Michael M¹, Price T², Ganju V³, Strickland A⁴, Jefford M¹, Muller A⁵, Ngan S¹, Milner A¹, Zalberg J¹

¹Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, ²Queen Elizabeth Medical Centre, Adelaide, Sth Australia, Australia, ³Frankston Hospital, Frankston, Victoria, Australia, ⁴Monash Medical Centre, Melbourne, Victoria, Australia, ⁵Adelaide Radiotherapy Centre, Adelaide, Sth Australia, Australia

P-012. Oxaliplatin-based chemotherapy in patients with advanced pancreatic cancer

Vattemi E¹, Franchi R², Pedersini R¹, Tansini G², Baier S¹, Costa P², Signaroldi A², Zanaletti F², Sbalzarini G², Graiff C¹

¹Division of Medical Oncology, Central Hospital, Bolzano, Italy., ²Division of Medical Oncology, Civic Hospital, Casalpusterlengo (LO), Italy.

P-013. Differential apoptosis by gallotannin in human colon cancer cells with distinct p53 status

Al-Ayyoubi S¹, **Gali-Muhtasib H²**

¹American University of Beirut, Beirut, Lebanon, ²American University of Beirut, Beirut, Lebanon

P-014. Expression of E-cadherin, beta-catenin, and CD44v6 in metastatic colon adenocarcinomas

Delektorskaya V, Perevoschikov A, Kushlinsky N

N.N.Blokhin Russian Cancer Research Centre, Moscow, Russian Federation

P-015. Induction of apoptosis and protection against DMH-induced colon cancer by the extract of onopordum cynarocephalum

El-Najjar N¹, Saliba N², Talhouk S², **Gali-Muhtasib H⁴**

¹Department of Biology, American University of Beirut, Lebanon, ²Department of Chemistry, American University of Beirut, Beirut, Lebanon, ³Department of Plant Sciences, American University of Beirut, Beirut, Lebanon, ⁴Department of Biology, American University of Beirut, Beirut, Lebanon

P-016. Two colons-two cancers: is right colon cancer different from the left one?

Evangelista W¹, Racca P², Fanchini L¹, Ritorto G², Milanese E², Napoletano R¹, Angelini F¹, Facilissimo I², Bertetto O¹, Ciuffreda L¹

¹COES-Centro Oncologico ed Ematologico Subalpino ASO San Giovanni Battista, Torino, Italy, ²CURO-Centro Universitario di Ricerca Oncologica ASO San Giovanni Battista, Torino, Italy

P-017. Intrinsic denervation of the colon reduces colonic preneoplastic markers in rats treated with a chemical carcinogen

Garcia S¹, Vespúcio M¹, Turatti A¹, Modiano P¹, Oliveira E², Chicotte S¹, Pinto A¹

¹Faculty of Medicine of Ribeirão Preto - University of São Paulo, Brazil, ²Federal University of Goias

P-018. Stimulatory action of pinealectomy on the rat colon carcinogenesis

Garcia W, Silva J, Garcia S, Zucoloto S

Faculty of Medicine of Ribeirão Preto - University of São Paulo

P-019. Metabolomics - a new approach for the detection of colon cancer?

Hartmann M¹, Baumbach J¹, Nolte J¹, Moyer M², Zimmermann D¹

¹ISAS-Institute for Analytical Sciences, Dortmund, Germany, ²Incell

P-020. Drugs effective for prevention of colon adenomas

Jacoby R¹, Cole C¹, Lubet R²

¹University of Wisconsin, Madison, WI, USA, ²Chemoprevention Branch, National Cancer Institute, Bethesda, MD, USA

P-021. "Colonoscope with disposable cartridges": Self-propelling - does not need disinfection!

Matasov S, Borisova A

RD Center CONTRA CANCRUM COLI

P-022. Estrogenic regulation of cannabinoid CB1 receptor gene expression in human colon cancer cell lines

Notarnicola M², Orlando A², Messa C², Gazzero P¹, Laezza C³, D'Attoma B², Bifulco M¹, Caruso M²

¹Università Studi di Salerno - Dipartimento di Scienze Farmaceutiche, Fisciano (Salerno), Italy,

²Laboratory of Biochemistry, National Institute for Digestive Diseases - Castellana Grotte - Bari, ³Istituto di Endocrinologia ed Oncologia Sperimentale, IEOS, CNR - Napoli

P-023. All-trans retinoic acid induces XAF1 expression through an interferon regulatory factor-1 element in colon cancer

Wang J¹, Jiang B¹, Zhang Y¹, Zhi F¹, Chen C¹, Zhang Z¹, Wong B

¹Department of Digestive Medicine, Nanfang Hospital, Guangzhou, China, ²Department of Medicine, The Hong Kong University, Hong Kong

P-024. Expression of survivin variants in colon cancer

Yoon J, Namgung H, Park D

Dankook University, Cheonan, Korea

P-025. Digestive cancer in Buenos Aires Province, Argentina: Focusing in epidemiology

Bonicatto S, Mainella A, Lavezzaro M, Troncoso E, Barbero A, Zapata Caamaño G

San Roque Hospital; Gonnet, Argentina

P-026. Cetuximab activity in elderly patients with extensively pretreated metastatic colorectal cancer

Bouchahda M¹, Bachet J², André T³, Afchain P⁴, Louvet C⁴, Landi B⁵, Karaboué A¹, Julié C², Lévi F¹,

Rougier P²

¹Hopital Paul Brousse, Villejuif, France, ²Hôpital Amboise Paré, Paris, France, ³Hôpital Tenon, Paris, France,

⁴Hôpital Saint Antoine, Paris, France, ⁵Hôpital Européen Georges Pompidou, Paris, France

P-027. Adjuvant chemotherapy for colon cancer: Should we simplify the folfox4 regimen?

Brixi-benmansour H¹, Bouché O¹, Thé C¹, Burde F¹, Garcia B², Lagarde S¹

¹Gastroenterology, CHU Reims, France, ²Clinique Courlancy, Reims, France

P-028. DHA Induces proteasomal degradation of b-catenin and apoptosis in human colorectal cancer cells not expressing COX-2

Calviello G¹, Resci F¹, Serini S¹, Piccioni E¹, Toesca A², Currò D³, Rannelletti F⁴, Palozza P¹

¹Institute of General Pathology, Catholic University, Rome , Italy, ²Institute of Human Anatomy, Catholic University, Rome , Italy, ³Institute of Pharmacology, Catholic University, Rome, Italy, ⁴Institute of Histology, Catholic University, Rome , Italy

P-029. The lymph node ratio is a better prognostic factor than the UICC pN-stage in node-positive colorectal cancer.

De Ridder M, Vinh-Hung V, Sermeus A, Van Nieuwenhove Y, Storme G
Oncology Center AZ-VUB, Brussels, Belgium

P-030. Dose intensity chemotherapy in adjuvant colorectal cancer with FOLFOX-4 regimen.

Evangelista W¹, Racca P², Fanchini L¹, Ritorto G², Volpato R¹, Ciorba A¹, Facilissimo I², Napoletano R¹, Bertetto O¹, Ciuffreda L¹

¹COES-Centro Oncologico ed Ematologico Subalpino ASO San Giovanni Battista, Torino, Italy, ²CURO-Centro Universitario di Ricerca Oncologica ASO San Giovanni Battista, Torino, Italy

P-031. Allergic-type reactions to oxaliplatin: Retrospective analysis of 160 patients (pts)

Evangelista W, Racca P, Fanchini L

COES-Centro Oncologico ed Ematologico Subalpino ASO San Giovanni Battista, Torino, Italy

P-032. Deep electro-hyperthermia with radiofrequencies combined with thermo-active drugs in patients with liver metastases from colorectal cancer (CRC): A phase II clinical study

Fiorentini G, De Giorgi U, Turrisi G, Rossi S, Dentico P, Bernardeschi P

Department of Oncology ASL 11 City Hospital S. Giuseppe, Empoli , Italy

P-033. Neoadjuvant chemotherapy including bevacizumab in potentially curable metastatic colorectal cancer

Gruenberger B¹, Scheithauer W¹, Tamandl D², Puhalla H², Kornek G¹, Zielinski C¹, Gruenberger T²

¹Medical University Vienna, Dep of Internal med I, Vienna, Austria, ²Medical university Vienna, Dep of general surgery , Vienna, Austria

P-034. CTLA-4 gene promoter and exon 1 polymorphisms in Iranian patients with gastric and colorectal cancers

Hadinia A¹, Hosseini S², Saberi-Firoozi M³, Erfani N¹, **Ghaderi A**¹

¹Shiraz Institute for Cancer Research and Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran, ²Department of Surgery, Shiraz University of Medical Sciences, Shiraz, Iran,

³Department of Internal Medicine and Gastroenterology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

P-035. Ibandronic acid and radiotherapy in the treatment of bone metastasis in colorectal cancer patients

Heras P^{1,2}, Hatzopoulos A^{1,2}, Karagiannis S¹

¹General Hospital of Nafplio. Department of Internal Medicine, Athens, Greece, ²Hellenic Medical Society for the Study of Psychosomatic Problems

P-036. Prevention of delayed emesis in patients with colorectal cancer due to moderately and highly emetogenic chemotherapy: Superiority of twice daily vs once daily oral methylprednisolone in combination with granisetron

Heras P^{1,2}, Hatzopoulos A^{1,2}, Karagiannis S¹

¹General Hospital of Nafplio. Department of Internal Medicine, Athens, Greece, ²Hellenic Medical Society for the Study of Psychosomatic Problems

P-037. Sleep disorders in patients with colorectal cancer in correlation with quality of life and awareness of disease

Heras P^{1,2}, Hatzopoulos A^{1,2}, Karagiannis S¹

¹General Hospital of Nafplio. Department of Internal Medicine, Athens, Greece, ²Hellenic Medical Society for the Study of Psychosomatic Problems

P-038. Correlation between matrix metalloproteinase-9 immunohistochemistry and mRNA expression array results in colorectal cancer

Herszenyi L, Sipos F, Galamb O, Hritz I, Molnar B, Tulassay Z

2nd Dept. Medicine, Semmelweis University, Budapest, Hungary

P-039. Correlation of thymidylate synthase protein expression and microsatellite instability in colorectal cancer.

Jensen H, Lindebjerg J, Crüger D, Jakobsen A
Danish Colorectal Cancer Group South, Vejle, Denmark

P-040. Fraction of LOH on chromosome 17 and 18 (LOH-ratio) correlates LOH on other chromosomes and predicts colorectal cancer outcome

Kanazawa T, Watanabe T, Nagawa H
University of Tokyo, Tokyo, Japan

P-041. Capecitabine plus irinotecan in combination with bevacizumab in chemo-naïve metastatic colorectal cancer, pilot study

Kocakova I, Lakomy R, Spelda S, Kocak I, Vyzula R
Masaryk Memorial Cancer Institute

P-042. Clinicopathologic features of multiple primary cancer in colorectum and stomach

Lee W, Park C, Lee W, Yun S, Chun H, Kim S, Noh H, Sohn T
Samsung Medical Center, Seoul, South Korea

P-043. KRAS mutation status is predictive of response to Cetuximab therapy in colorectal cancer

Lièvre A^{1,2}, Bachet J¹, Boige V³, Landi B⁴, Emile J¹, Côté J^{2,4}, Tomasic G³, Rougier P¹, Penault-Llorca F⁵, Laurent-Puig P^{2,4}

¹Assistance Publique-Hôpitaux de Paris, Hôpital Ambroise Paré, Boulogne Billancourt, France, ²Université Paris-Descartes; INSERM, UMR-S775 Paris, France., ³Institut Gustave Roussy, Villejuif, France,

⁴Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France, ⁵Centre Jean Perrin, Clermont-Ferrand, France

P-044. Novel epigenetic mechanism for transcriptional silencing of e-cadherin in colorectal cancers

Liu Y, Hong Y, Zhao Y, Seow Choen F, Eu K
Singapore General Hospital, Singapore

P-045. Analysis of exfoliated colonic cells and colorectal cancer detection

Loktionov A¹, Lywood H¹, Bandaletova T¹, Llewelyn A¹, Ferrett C², Gibson J³, Lywood R¹, Broughton M⁴, Caffarey S⁴, Marks C⁴

¹Colonix Ltd, Cambridge, UK, ²John Radcliffe Hospital, Oxford, UK, ³Honiton Hospital, Honiton, UK, ⁴Royal Surrey County Hospital, Guildford, UK

P-046. Mutational analysis of biopsy DNA obtained from colonoscopy positive patients in western Norway

Lovlie R¹, Hart H², Ostborg J³, Aloysius T¹, Ogreid D¹, **Parker D**¹

¹Nordiag ASA, Bergen, Norway, ²Gastro Nova, Stavanger, Norway, ³Gastrolegegruppen, Haugesund, Norway

P-047. Colorectal cancer in Canada, 1981-2001 - A population based study of epidemiology and surgical treatment

Mao Y, Waters C, Xie L, Gao R
Public Health Agency of Canada, Ottawa, Canada

P-048. Human papillomavirus (HPV) infection, p53 overexpression and histopathologic factor in colorectal cancer

Motlagh A¹, **Azadeh P**¹, Hashemi M², Molaei M⁴, Shafaghi B², Davaei M³, Fazlalizadeh A¹, Alidoosti A¹, Ghaderi F⁴, Noorinayaer B⁴

¹Department of Radiation oncology, Imam Hossien Hospital, Shahid Beheshti University, Tehran, Iran ;,

²Department of Pathology, Imam Hossien Hospital, Shahid Beheshti University, Tehran, Iran ;d,

³Department of Surgery, Imam Hossien Hospital, Shahid Beheshti University, Tehran, Iran ;, ⁴The Research Center for Gastroenterology and Liver Disease (RCGLD) e, Taleghani Hospital, Shahid Beheshti University, Tehran, Iran.;

P-049. Pharmacokinetics of Irinotecan and SN38 after intra-arterial liver perfusion according to infusion time and circadian patient pattern in metastatic colorectal cancer

Nasisi A¹, Pirovano M¹, Scaglione F², Fornasari D², Paraboni L¹, Sestini S¹, Rivolta R¹, Ventura P¹, Meregalli M¹, Tabiaddon D¹

¹Oncology Dept.Ospedale San Carlo Bo, ²Pharmacology Dept. Milan School of Medicine

P-050. The role of hemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer (ACC) patients.

Nasisi A¹, Pirovano M¹, Sestini S¹, Paraboni L¹, Scaglione F², Masseroni S¹, Gherardi F¹, Martignoni G¹, Meregalli M¹, Tabiaddon D¹

¹Oncology Dept.Ospedale San Carlo Borromeo, Milan, Italy, ²Pharmacology Dept. Milan School of Medicine, Milan, Italy

P-051. Can bevacizumab be safely administered to all colorectal cancer (CRC) patients older than 70 years?

Pasetto L, Falci C, Sinigaglia G, Monfardini S

Istituto Oncologico Veneto: Oncology Division, Padova, Italy

P-052. Genetic polymorphisms of MTHFR and TS genes and risk of sporadic colorectal cancer in Romanian patients

Procopciuc L¹, Osian G², Olteanu I¹, Jebeleanu G³, Vlad L²

¹Department of Medical Biochemistry, University of Medicine and Pharmacy Cluj-Napoca Romania,

²Department of Surgery, University of Medicine and Pharmacy Cluj-Napoca Romania, ³Department of Medical Biochemistry, University of Medicine and Pharmacy, Oradea Romania

P-053. Correlation of microsatellite instability (MSI) status with clinical parameters and treatment outcomes for patients with metastatic colorectal cancer (MCC) treated with a triplet combination with irinotecan (CPT-11), Oxaliplatin (L-OHP) plus bolus and infusional 5FU/LEUCOVORIN (DeGramont regimen)-FOLFOXIRI

SOUGLAKOS I¹, Papadatos-Pastos D¹, Tzardi M², Saridaki Z¹, Zois N³, Peraki M⁴, Mavroudis D¹, Georgoulas V¹

¹Dep of Med Oncology University Hosp of Hersklion, ²Dep of Pathology University Hosp of Hersklion, ³Dep of Pathology Venizelio General Hospital, ⁴Laboratory of Cancer Biology, Medical School of Crete University of Crete

P-054. EGFR SP1 -216 G/T polymorphism in colorectal cancer

Spindler K, Nederby Nielsen J, Lindebjerg J, Brandslund I, Jakobsen A

Danish Colorectal Cancer Group South, Vejle Hospital

P-055. Endoscopical therapy in non operating colorectal cancers

Uzunova A¹, Uzunov H², Karkamov M¹, Nakov H²

¹MDC, ²MMA

P-056. The role of Src-family kinases in the activation of the EGFR following chemotherapy.

Van Schaeybroeck S^{1,2}, Longley D¹, Kyula J¹, Kelly D¹, Van Cutsem E², Johnston P¹

¹Queen's University Belfast, UK, ²UZ Gasthuisberg Leuven, Belgium

P-057. Suppression of FHL2 expression induces cell differentiation and inhibits gastrointestinal carcinogenesis

Wang J¹, Zhang Y¹, Zhi F¹, Chen C¹, Zhang Z¹, Jiang B¹, Wong B²

¹Department of Digestive Medicine, Nanfang Hospital, Guangzhou, China, ²Department of Medicine, The University of Hong Kong, Hong Kong, China

P-058. Cell cycle-oriented dose-dense chemotherapy: High-dose shorter plus low-dose metronomic regimen

Yoshikawa R^{1,2}, Yanagi H¹, Noda M¹, Fujiwara Y¹, Yagyu T¹, Gega M¹, Oshima T¹, Yamamura T¹, Hashimoto-Tamaoki T^{2,3}

¹Second Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan, ²Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Japan, ³Department of Genetics, Hyogo College of Medicine, Nishinomiya, Japan

P-059. Low rectal cancers at the intersphincteric plane are at high risk of close resection margins: An analysis of the MERCURY Study MRI scans

Salerno G¹, Daniels I¹, Brown G²

¹Pelican Cancer Foundation, Basingstoke, UK, ²Royal Marsden Hospital, UK

P-060. 5-FU and CPT-11 significantly reduce intraperitoneal tumor growth in experimental investigations of peritoneal carcinomatosis

Hribaschek A¹, Meyer F¹, Pross M, Ridwelski K, Schneider-Stock R, Lippert H

¹University of Magdeburg Dep.for Surgery, ²Dep. for Surgery Municipal Hospital of Magdeburg, ³University of Magdeburg Dep. for Pathology

P-061. Long- term survival after extended lymphadenectomy in negative margin resectable (R0) rectal cancer.

Popiela T, Kulig J, Richter P, Bucki K

Jagiellonian University I Dept.of Surg Kraków Kopernika, Poland

P-062. Oncologic outcome in laparoscopic and open total mesorectal excision.

Staudacher C, Di Palo S, Vignali A, Tamburini A, Orsenigo E

San Raffaele Scientific Institute. Department of Surgery. University Vita-Salute San Raffaele, Milan, Italy

P-063. Sentinel node mapping in colon carcinoma: In-vivo versus ex-vivo approach

Tuech J, Bridoux V, Lefebure B, Di Fiore F, Lubrano J, Michot F

University Hospital Rouen France

P-064. Long-term hypoxic no-reflow contributes to ischemia/reperfusion-accelerated outgrowth of colorectal micrometastases in the murine liver.

van der Bilt J¹, Soeters M¹, Pieters A¹, Witteveen P¹, van Diest P¹, Kranenburg O¹, Borel Rinkes I¹

¹Dept of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands, ²Dept of Medical Oncology, UMC Utrecht, Utrecht, The Netherlands, ³Dept of Pathology, UMC Utrecht, The Netherlands

P-065. Tumor gene expression influences the chance of cure and the type of recurrence after colectomy in a colon cancer model using mice grafts.

Welschbillig K¹, Ferron M¹, Flejou J², Aime A¹, Praz F¹, Pocard M¹⁻³

¹Unité INSERM 762 , Paris, France, ²Saint Antoine Hospital - Paris, France, ³Lariboisière Hospital - Paris, France

P-066. Phase II trial of neoadjuvant chemotherapy in operable epidermoid esophageal carcinoma

Abdel Salam M¹, Amin T¹, Elweshi A¹, Alhusseiny H¹, Rehman K¹, Ajarim D¹, Memon M¹, Bazarbashi S¹

¹King Faisal Specialist Hospital and Research Center, ⁶King Faisal Specialist Hospital and Research Center,

⁷King Faisal Specialist Hospital and Research Center, ⁸King Faisal Specialist Hospital and Research Center

P-067. Gastrointestinal cancers in northwestern of Iran

Ahmadi R, Shariaty A

Islamic Azad University, Hamedan Branch,Iran.

P-068. Exclusive chemoradiation for non-operable patients with stage I/II oesophageal cancer

Crehange G¹, Bosset M², Peignaux K¹, Servagi - Vernat S², Puyraveau M³, Buffet - Miny J², Mercier M³, Bosset J², Maingon P¹

¹Centre Georges François Leclerc, Department of Radiotherapy, 21000 DIJON, ²Hospital Jean Minjoz, Department of Radiotherapy, 25000 BESANCON, FRANCE, ³University of Franche Comte, Department of Biostatistics, 25000 BESANCON, FRANCE

P-069. Outcomes of oesophagectomy for carcinoma: One Institution experience and analysis of 126 patients

Dionigi G, Boni L, Rovera F, Annoni M, Dionigi R

University of Insubria Department of Surgical Sciences, Varese, Italy

P-070. Surgical treatment for carcinoma of oesophagus and oesophagogastric junction in small thoracic unit

Krdzalic G¹, Mesic D, Ramic N, Musanovic N

¹Clinical Center Tuzla, ²Clinical center Tuzla

P-071. The prognostic significance of cyclooxygenase-2 (COX-2) hypermethylation for patients of esophageal cancer.

Lee J¹, Liu T², Kuo S¹, Hsu H¹, Huang P¹, Chen J¹, Lee Y¹

¹National Taiwan University Hospital, Taipei, Taiwan, ²Department of Internal Medicine, and ²Department of Medical Research and Education, Veteran General Hospital

P-072. Complications after oesophageal resection for primary cancer: the role of blood transfusions

Rovera F, **Dionigi G**, Boni L, Tabacchi A, Dionigi R
Department of Surgical Sciences, University of Insubria, Varese, Italy

P-073. Are von Willebrand Factor and Ki-67 outcome predictors for esophageal cancer?

Van Damme N¹, Demetter P², Delmotte I¹, Ceelen W³, Pattyn P³, Monsaert E¹, Boterberg T⁴, Peeters M¹
¹Ghent University Hospital, Dept. of Gastroenterology, Ghent, Belgium, ²Erasmus University Hospital, Dept. of Pathology, Brussels, Belgium, ³Ghent University Hospital, Dept. of Surgery, Ghent, Belgium, ⁴Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium

P-074. Weekly docetaxel as monotherapy in advanced gastric cancer. Efficacy and safety in pre-treated patients, elderly patients or patients with an impaired performance status.

Abbrederis K¹, Lorenzen S¹, Duyster J¹, Fischer von Weikersthal L², Seroneit T³, Röthling N⁴, Peschel C¹, Lordick F¹
¹Klinikum rechts der Isar, Technical University of Munich, Germany, ²Klinik St. Marien, Amberg, Germany, ³Sanofi-Aventis GmbH, Berlin, Germany, ⁴Center for Clinical Studies, Technical University of Munich, Germany

P-075. Impact of adjuvant 3-D conformal radiation concomitant with chemotherapy in gastric cancer: Analysis of acute toxicity.

Carballo-Castro A¹, **Graña-Suárez B**², Gómez-Caamaño A¹, Sevillano Capeán M¹, Curiel García M², Luis León Mateos L², Peleteiro Higuero P¹, García González J², Castro Gómez E¹, Herranz Anido U²
¹Radiotherapy Department, Complejo Hospitalario Universitario. Santiago de Compostela, SPAIN, ²Medical Oncology Department, Complejo Hospitalario Universitario. Santiago de Compostela, SPAIN

P-076. Anti-tumor effects and drug interaction of proteasome inhibitor bortezomib (PS341) for gastric cancer cell

Fujita T¹, Washio K², Ino H¹, Murakami M¹, Naito M¹, Doihara H¹, Shimizu N¹
¹Okayama University School of Medicine, Okayama, Japan, ²Okayama Rosai Hospital, Okayama, Japan

P-077. The effects of helicobacter pylori infection on carcinogenesis in the gastric remnant after distal gastrectomy for cancer

Fukuhara K, Osugi H, Takemura M, Lee S, Nishikawa T, Nishikawa H
Osaka City University Graduate School of Medicine, Osaka, Japan

P-078. Infectious agent as a gastric cancer causes - Fact or possibility

Jakovljevic B, Rakita I, Jungic S, Gojkovic Z, Raseta R, Vranjes Z
Clinic of oncology Clinical Center, Banja Luka, BOSNIA-HERZEGOVINA

P-079. GIST: A ten years review and our findings in the literature.

Jiménez R, Bermejo A, Sousa J, Covacho D, Palacios C, Galindo A
Hospital Universitario Virgen del Rocío, Sevilla, Spain

P-080. Prognostic and clinical features of gastric cancer patients in Pakistani population.

Lal A, alidina A, Gaffar A, Islam M, Jafari W
Aga Khan University, Karachi, Pakistan

P-081. Analysis of prognostic factors in gastric cancer by expression of molecular genetic markers

Lee W¹, Bae B¹, Park J¹, Song H²
¹Daegu Fatima Hospital, Daegu, Korea, ²Keimyung University Hospital, Daegu, Korea

P-082. Screening differentially expressed genes between primary and metastatic gastric adenocarcinomas by gene expression profile chip

Li M¹, Xin Y¹
¹Cancer Institute, No.1 Hospital, China Medical University, Shenyang 110001, Shenyang, China, ²Cancer Institute, No.1 Hospital, China Medical University, Shenyang 110001, Shenyang, China

P-083. Capecitabine with platinum-compounds in first-line chemotherapy of advanced gastric cancer (preliminary results).

Markovich A, Gorbounova V, Orel N, Besova N, Bruzgin V
Russian Cancer Research Center, Moscow, Russian Federation

P-084. Gastrokine 1 expression in patients with and without Helicobacter pylori infection

Martin G¹, Rocco A¹, Pica L¹, Siciliano R², Rippa L³, Arcari P³, Nardone G¹

¹Dipartimento di Medicina Clinica e Sperimentale, Unità di Gastroenterologia, Università di Napoli Federico II, Napoli, Italy;; ²Centro di Spettrometria di Massa Proteomica e Biomolecolare. Istituto di Scienze dell'Alimentazione – CNR. Avellino, Italy;; ³Dipartimento di Biochimica e Biotecnologie Mediche, Università di Napoli Federico II, Napoli, Italy;

P-085. Endogastric capsule (EC) for determining E-Cadherin gene (CDH-1) promoter hypermethylation in DNA isolated from gastric juice.

Muretto P¹, Ruzzo A², Graziano F³, Pizzagalli F², Staccioli M¹, Magnani M²

¹Institute of Histopathology, Hospital of Pesaro, Pesaro, Italy, ²Institute of Biochemistry, University of Urbino, Italy, ³Medical Oncology Unit, Hospital of Urbino, Italy

P-086. Endogastric capsule (EC) for molecular analysis of helicobacter pylori (HP) infection and gastric pH.

Muretto P¹, Staccioli M¹, Ruzzo A², Graziano F³

¹Institute of Histopathology, Hospital of Pesaro, Pesaro, Italy, ²Institute of Biochemistry, University of Urbino, Italy, ³Medical Oncology Unit, Hospital of Urbino, Italy

P-087. In vitro schedule-dependent interaction between Oxaliplatin and 5-Fluorouracil in human gastric cancer cell lines

Qin B, Tanaka R, Shibata Y, Arita S, Ariyama H, Kusaba H, Baba E, Harada M, **Nakano S**

First Department of Medicine, Kyushu Univeristy Hopital, Fukuoka, Japan

P-088. MDR1 P-glycoprotein expression and gastric cancer: Not only multi-drug resistemnce

Rocco A¹, Compare D¹, Martin G¹, D'Armiento M², Budillon G¹, Nardone G¹

¹Department of Clinical and Experimental Medicine, Gastroenterology, University Federico II, Naples, Italy,

²Department of Pathology, University Federico II, Naples, Italy

P-089. Gastrointestinal cancer risk evaluation in chernobyl clean-up workers

Seleznovs J, Pokrotnieks J, Orlikovs G, Farbtuh T, Zvagule T, Eglīte M

Paula Stradins Clinic University Hospital, Riga, Latvia

P-090. BMI and gastric emptying of the patients with gastric cancer

Soeda J, Ogoshi K, Nakamura K, Nabesima K

tokai university hospital department of surgery

P-091. Prognostic value of COX-2 expression in gastric cancer at early stage

Tamburini A¹, Tomajer V¹, Orsenigo E¹, Do Palo S¹, Albarello L², Doglioni C², Staudacher C¹

¹Vita-Salute San Raffaele University Dept of Surgery, ²San Raffaele Hospital Dept of Pathology

P-092. Inhibition of phosphorylated Akt/PKB involving in the antiproliferative and pro-apoptotic effects of apigenin on human gastric carcinoma cells

Wu K¹, Yuan L²

¹Harbin Medical University, ²Harbin Medical University

P-093. Studies on significance and expression of bax, survivin and p53 in gastric carcinoma and precancerous lesions using tissue microarray

Xint Y¹, Xiao Y², Wu D¹

¹4th Lab, Cancer Institute, No.1 Hospital, China Medical University, Shenyang, Liaoning, China, ²Cancer Institute, China Medical University, Shenyang, Liaoning, China, ³4th Lab, Cancer Institute, No.1 Hospital, China Medical University, Shenyang, Liaoning, China

P-094. The serum proteomic of the patients with gastric cancer: A preliminary study

Xue W, Xin Y

Cancer Institute, No.1 Hospital, China Medical University, Shenyang 110001, Shenyang, China

P-095. The difference of gene expression profile in human gastric cancer grafted onto nude mice treated with WCA

Zhao A, Yang J, You S, Li T, Zhao H, Gu Y, Tang L, Qiu J

Shanghai University of Traditional Chinese Medicine

P-096. Benign gastrointestinal stromal tumors: Personal experience

Diaconescu M

University of Medicine & Pharmacy, Iasi, Romania

P-097. Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy

Negri F¹, Campanini N², Camisa R¹, Pucci F¹, Bui S¹, Ceccon G³, Martinelli R³, Caruana P², Cascinu S⁴, Ardizzoni A¹

¹U.O. Oncologia Medica, Azienda Ospedaliero Universitaria di Parma, Italy, ²Istituto di Anatomia Patologica, Azienda Ospedaliero Universitaria di Parma, Italy, ³Servizio di Radioterapia, Azienda Ospedaliero Universitaria di Parma, Italy, ⁴Oncologia Clinica, Azienda Ospedaliera Universitaria Umberto I, Ancona, Italy

P-098. Clinical significance of bone marrow micro metastases in patients undergoing liver transplantation for hepatocellular carcinoma

Battula N¹, Sutcliffe R¹, Maguire D¹, Portmann B¹, Rela M¹, O'Sullivan G¹, Mufti G¹, Heaton N¹

¹Institute of liver studies, Cheyne Wings, Kings College Hospital, London, UK, ⁶Cork Cancer Research Centre, Mercy Hospital, Cork, Ireland, ⁷Department of Haematological Medicine, King's College Hospital, London, United Kingdom, ⁸Institute of liver studies, Cheyne Wings, Kings College Hospital, London, United Kingdom

P-099. Ruptured hepatocellular carcinoma following chemoembolisation: A rare complication

Battula N¹, Madanur M¹, Srinivasan P¹, Karani J², Heaton N¹, Rela M¹

¹Institute of liver studies, Cheyne Wing, Kings College Hospital, London, United Kingdom, ²Department of Radiology, Kings College Hospital, London, UK, ⁵Institute of liver studies, Cheyne Wing, Kings College Hospital, London, United Kingdom, ⁶Institute of liver studies, Cheyne Wing, Kings College Hospital, London, United Kingdom

P-100. Spontaneous rupture of Hepatocellular carcinoma : Kings College Hospital experience

Battula N¹, Madanur M, Priest O, Marangoni G, Srinivasan P, Karani J, Heaton N, Rela M

¹Kings College Hospital, Denmark Hill, London, SE5 9RS, U.K, ²Kings College Hospital, Denmark Hill, London, SE5 9RS, U.K, ³Kings College Hospital, Denmark Hill, London, SE5 9RS, U.K, ⁴Kings College Hospital, Denmark Hill, London, SE5 9RS, U.K, ⁵Kings College Hospital, Denmark Hill, London, SE5 9RS, U.K, ⁶Kings College Hospital, Denmark Hill, London, SE5 9RS, U.K, ⁷Kings College Hospital, Denmark Hill, London, SE5 9RS, U.K, ⁸Kings College Hospital, Denmark Hill, London, SE5 9RS, U.K

P-101. Treatment results in children with hepatoblastoma: A report from the Regional Cancer Centre in India

Chandra A¹, Sagar T², Mahajan V³

¹Department of Medical Oncology , Cancer Institute , Chennai , Tamil Nadu , India, ²Department of Medical Oncology , Cancer Institute , Chennai , Tamil Nadu , India, ³Department of Surgical Oncology , Cancer Institute , Chennai , Tamil Nadu , India

P-102. Treatment of unresectable nodular cholangiocarcinoma with yttrium-90 microspheres

Coldwell D¹, Kennedy A²

¹University of Texas, Dallas, TX, ²Wake Radiology Oncology, Carey, NC

P-103. Assessment of viable tissue attached to needle electrodes after local ablation of liver tumors

Jansen M^{1 and 2}, Snoeren N¹, Rijken A², van Hillegersberg R³, Slooter G⁴, Klaase J⁵, van der Tol P⁶, van der Linden E⁷, ten Kate F¹, van Gulik T¹

¹Academic Medical Centre, Amsterdam, Netherlands, ²Amphia Hospital Breda, ³Utrecht Medical Centre, ⁴Maxima Medical Centre, ⁵Medisch Spectrum Twente, ⁶VU Medical Centre, ⁷Leiden University Medical Centre

P-104. Utility of CA 19 9 in denovo arising cholangiocarcinomas.

John A, Haghighi K, Taniere P, Esmat E, Bramhall S

Queen Elizabeth Hospital

P-105. MR imaging and MR cholangiopancreatography in the preoperative evaluation of hilar cholangiocarcinoma: Correlation with surgical and pathologic findings

Masselli G, Casciani E, Poletini E, Bertini L, Lanciotti S, Gualdi G

Radiology Emergency Department "La Sapienza" University, Roma, Italy

P-106. Surgical treatment of bilobar hepatic metastases

Nikolic S, Inic M, Kocic M, Marjanovic B, Martinovic A, Zegarac M, Djuricic I, Miletic N
Institute For Oncology And Radiology of Serbia

P-107. Liver resection after neoadjuvant chemotherapy for unresectable colorectal metastases

Noguera J, Arrivi A, Vicens J, Morales R, Ibarra J, Dolz C, Pujol J
Hospital Son Llàtzer, Palma, Spain

P-108. Safe surgery for colorectal cancer liver metastases using modern dissection techniques.

Tamandl D¹, Gruenberger B², Herberger B¹, Schoppmann S¹, Bodingbauer M¹, Fleischmann E³, Schima W⁴, Jakesz R¹, Laengle F¹, Gruenberger T¹

¹Dept. Surgery, Vienna Medical University, ²Division of Oncology, Department of Medicine I, ³Department of Anaesthesiology and Intensive Care, ⁴Department of Radiology

P-109. Percutaneous cryoablation combined with ethanol injection in unresectable primary hepatocellular carcinoma

Xu K, Niu L, He W, Guo Z, Hu Y, Zuo J
Guangzhou Fuda Cancer Hospital, Guangdong, China

P-110. Systemic chemotherapy as initial treatment for patients with locally advanced unresectable pancreatic cancer: a valid option?

Bachet J¹, Mitry E¹, Declety G¹, Vaillant J³, Peschard F¹, Benoist S¹, Housset M², Otmegzguine Y³, Nordlinger B¹, Rougier P¹

¹Ambroise Paré Hospital, Boulogne Billancourt, France, ²Geoges Pompidou European Hospital, ³Clinique de la porte de St Cloud

P-111. Nutritional and pharmacologic support in patients with pancreatic carcinoma; Our results

Bagic Z¹, Dobrila-Dintinjana R¹, Djipalo I¹, Dintinjana M², Stimac D¹

¹Clinical Hospital Center Rijeka, Internal Clinic, Gastroenterology Dept., Rijeka, Croatia, ²Private Practice Ambulance, Croatia

P-112. Analysis of quality of life in patients with pancreatic cancer

Brasiuniene B¹, **Brasiunas V**², Juozaityte E³

¹Kaunas Medical University Clinics Oncology Hospital, ²Kaunas Medical University Clinics Department of Oncology, ³Kaunas Medical University Clinics Department of Oncology

P-113. The efficacy of two combined treatment methods in patients with pancreatic cancer

Brasiuniene B, **Brasiunas V**, Juozaityte E
Kaunas Medical University Clinics Oncology Hospital

P-114. PEFG salvage therapy in patients with gemcitabine-resistant advanced pancreatic cancer (PC)

Cereda S¹, Mazza E¹, Passoni P², Nicoletti R³, Balzano G⁴, Zerbi A⁴, Staudacher C⁴, di Carlo V⁴, Reni M⁴

¹Department of Oncology, S. Raffaele Scientific Institute, Milan, Italy, ²Department of Radiotherapy, S. Raffaele Scientific Institute, Milan, Italy, ³Department of Radiology, S. Raffaele Scientific Institute, Milan, Italy, ⁴Department of Surgery, S. Raffaele Scientific Institute, Milan, Italy

P-115. Preliminary data of safety and tolerability of adjuvant chemoradiotherapy after potentially curable surgery for pancreatic cancer. A single center experience

Deptala A¹, Asendrych A¹, Skowronska-Gardas A², Chojnacka M², Pedziwiatr K², Omyla-Staszewska J¹, Magon M¹, Soborczyk A¹

¹Department of Hematology, Oncology and Internal Medicine, Warsaw Medical University, Warsaw, Poland, ²Department of Radiation Oncology, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology

P-116. Gemcitabine and oxaliplatin in advanced pancreaticobiliary cancers: The Ohio State University experience

Fortune B, Kosuri K, Weatherby L, Young D, Xu Y, Muscarella P, Ellison C, Thomas J, **Bekaii-Saab T**
The Ohio State University, Columbus, USA

P-117. Anthropometrical approach to estimate a human body volume

Gerina-Berzina A¹, Diksit G², Dehtjar J², Vetra J²

¹Paula Stradins University Hospital, Riga, Latvia, ²Riga Technical University, Riga, Latvia

P-118. Biochemoimmunotherapy consisting of autologous tumor derived freeze-dried exosomes with resuspended encapsulated vinorelbine termed as exosomal vinorelbine tartrate (EVT) (under patent) induces apoptosis in pancreatic Ca.

Giannios J¹, Lambrinos P², Alexandropoulos N³
¹ACR, Oncology, ²PF, Oncology, ³IH, Biopathology

P-119. ACRITx-chemoradioimmunotherapy consisting of antiCaSm scFv linked onto high energy radioisotopes, vinorelbine and 21-nucleotide double stranded siRNA targeted to DNMT1 induce PCD in pancreatic and periampullary Ca.

Giannios J¹, Lambrinos P², Alexandropoulos N³
¹ACR Oncology, Attiki, Greece, ²PF Oncology, ³IH Biopathology

P-120. Phase II study of bevacizumab plus gemcitabine and capecitabine in patients with advanced pancreatic cancer with ECOG PS 0-1

Javle M¹, Wallace P¹, Yu J¹, Phelan J², Wilkinson Q¹, Litwin A¹, Nava H¹, Gibbs J¹, Kuvshinoff B¹, Iyer R¹
¹Roswell Park Cancer Institute, Buffalo, NY, ²Rochester General Hospital

P-121. Chylous ascites after Whipple's procedure: An early sign of tumour recurrence?

Madanur M, Battula N, Rela M
Kings College Hospital, Denmark Hill, London, UK

P-122. Endoscopic palliative biliary drainage in malignant tumors of the hepatobiliopancreatic system.

Malinger S
Department of General, Gastroenterological and Endokrynological Surgery, Poznań, Poland

P-123. The efficacy of Fluoropyrimidine-based second line chemotherapy in advanced and metastatic pancreatic cancer: Results of an ongoing retrospective multicenter study

Mancuso A¹, Saletti P², Sacchetta S¹, Romagnani E², Aprile G³, Fatigoni S⁴, Garassino M⁵, Saggese M⁶, Cavalli F², Sternberg C¹
¹San Camillo/Forlanini Hospital, Rome, Italy, ²Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, ³Medical Oncology Department, PUGD, Udine, Italy, ⁴Medical Oncology Department, Silvestrini Hospital, Perugia, Italy, ⁵Medical Oncology Department, Igea Hospital, Milan, Italy, ⁶Medical Oncology Department, Careggi Hospital, Florence, Italy

P-124. Pain in the advanced pancreatic carcinoma: CT-guided celiac neurolysis

Mauri E¹, de Sanctis V², Querol V¹, Arias I², Montull C¹, Mundt E¹, Martinez A¹, Llaverias S¹, Folch J², Casas D¹
¹Department of Radiology. Hospital Sagrat Cor, Barcelona, Spain, ²Pain Unit, Hospital Sagrat Cor, Barcelona, Spain

P-125. Phase II trial on biweekly high-dose gemcitabine for advanced pancreatic and biliary adenocarcinoma

pinotti g, martinelli b, rodolfo Masera g, schiavone g
Oncologia Medica - Ospedale di Circolo; Varese - Italy

P-126. Prognostic factors in patients undergoing resections for pancreatic ductal carcinoma.

Popiela T, Kulig J, Sierżęga M
Jagiellonian University I Dept. of Surg Kraków Kopernika, Poland

P-127. Impact of adjuvant chemoradiation after pancreaticoduodenectomy in periampullary carcinoma.

Rastogi N, Kumar S, Lal P, Dimri K, Sikora S, Kapoor V, Jain M
Sanjay Gandhi PG Inst of Med Sciences, Lucknow, India

P-128. Outcomes of chemoradiation for locally advanced pancreatic cancer at Ipswich Hospital 2002 - 2005

Tipples K¹, Soomal R¹, Sherwin E¹, Taylor-Neale P¹, Poynter A¹, Satyadas T¹, Xie S², Fanshawe T²
¹Oncology Department, Ipswich Hospital NHS Trust, Suffolk, UK, ²Centre for Applied Medical Statistics, University of Cambridge, UK

P-129. Survey of Cetuximab activity in irinotecan-refractory metastatic colorectal cancer patients
Bachet J¹, Afchain P², Bouchahda M³, Landi B⁴, André T⁵, Mitry E¹, Lièvre A¹, Levi F³, Rougier P¹, Louvet C²

¹Ambroise Pare Hospital, ²Saint Antoine Hospital, ³Paul Brousse Hospital, ⁴Georges Pompidou European Hospital, ⁵Tenon Hospital

P-130. Italian economic evaluation of capecitabine (X) vs. bolus 5-FU/LV as adjuvant chemotherapy for patients (pts) with Dukes' c colon cancer

Di Costanzo F¹, Sobrero A², Twelves C³, Douillard J⁴, Giuliani G⁵, Patel K⁶, Garrison L⁷, Cassidy J⁸
¹AO Careggi Department Oncologia Medica, Firenze, Italy, ²Ospedale S Martino, Genova, Italy, ³University of Leeds and Bradford NHS Trust, Bradford, UK, ⁴Centre R Gauducheau, St Herblain, France, ⁵Roche Italy, Milan, Italy, ⁶Hoffmann-La Roche Inc., Nutley, NJ, USA, ⁷University of Washington, Seattle, WA, USA, ⁸Glasgow University, Glasgow, UK

P-131. Oxidative DNA damage and antioxidant defence in colon and gastric cancer

Dincer Y¹, Himmetoglu S¹, Akcay T¹, Ersoy Y², Tortum O²

¹Istanbul University Cerrahpasa Medical Faculty Department of Biochemistry, Istanbul, Turkey, ²Istanbul University Cerrahpasa Medical Faculty Department of General Surgery

P-132. Juvenile polyposis syndrome in children: The need for colonic surveillance.

Elitsur Y

Marshall University, Huntington, USA

P-133. Capecitabine (X) vs. Mayo Clinic and de gramont 5-FU/LV regimens for stage III colon cancer: cost-effectiveness analysis in the French setting

Hussein F¹, Douillard J², Ychou M³, Perrocheau G², Tilleul P⁵, Maes P⁶, Dufour P⁷, Seitz J⁸

¹Hopitaux civils de Colmar, Colmar, France, ²Centre Renée Gauducheau, Nantes, France, ³Val d'Aurelle, Montpellier, France, ⁴Centre Renée Gauducheau, Nantes, France, ⁵Hospital Saint Antoine, Paris, France, ⁶Polyclinique du Bois, Lille, France, ⁷Centre Paul Strauss, Strasbourg, France, ⁸CRLC Hopital la Timone, Marseille, France

P-134. RNA analysis of paraffin-embedded archival colorectal cancer tissues: technical aspects and confirmation of predictive value of TS, DPD and TP expression

Imyanitov E, Iyevleva A, Buslov K, Filimonenko V, Matsko D, Suspitsin E, Kuligina E, Togo A, Moiseyenko V

N.N. Petrov Institute of Oncology

P-135. Feasibility and toxicity of a modified protracted venous infusion de gramont regimen in adjuvant colorectal cancer: A pilot study

Ionta M, Capra D, Atzori F, Esposito I, Deidda M, Carta A, Murgia M, Urraci Y, Pusceddu V, Massidda B
Department of Medical Oncology University of Cagliari, Italy .

P-136. Measurement of apoptotic index (AI) using an antibody against the active form of Caspase-3 as a prognostic factor in Stage II colon cancer

Park K¹, Choi H¹, Kim S¹, Shin J¹, Roh M², Kwon H³, Kim S³, Hong Y⁴, Sin J⁵, Cho H⁶

¹Department of Surgery, Dong-A University College of Medicine, Pusan, South Korea, ²Department of Pathology, Dong-A University College of Medicine, Pusan, South Korea, ³Department of Internal Medicine, Dong-A University College of Medicine, Pusan, South Korea, ⁴Department of Preventive Medicine, Dong-A University College of Medicine, Pusan, South Korea, ⁵Department of Surgery, Pusan Paik Hospital, Inje University College of Medicine, Pusan, South Korea, ⁶Department of Surgery, Pusan National University College of Medicine, Pusan, South Korea

P-137. 5 years survival results of intraperitoneal chemohyperthermia with oxaliplatin following cytoreductive surgery for peritoneal carcinomatosis.

Pocard M^{1,2}, Raynard B², Farkhondeh F², Goéré D², Rouquie D², Ciuchendea R², Ducreux M², Elias D²

¹Lariboisière Hospital, Paris, France, ²Gustave Roussy Institute, Villejuif, France

P-138. Prevalence of a positive cancer family history in GI cancer patients in a Canadian Province with high rates of cancer.

Virik K, Younis T

QE II Health Sciences Centre/Dalhousie University, Halifax, Canada

P-139. Preoperative colonoscopy after self-expandable metallic stent placement in patients with acute neoplastic colon obstruction

Vitale M, Villotti G, d'Alba L, Iacopini F, Iacopini G

Gastroenterology and Endoscopy Unit Azienda Ospedaliera San Giovanni-Addolorata, Rome, Italy

P-140. Cost-effectiveness of oxaliplatin/5FU/LV (FOLFOX) vs. irinotecan/5FU/LV (IFL) as first-line treatment of metastatic colorectal cancer

Aballea S¹, Najib M², Cure S¹, O'Neil B³

¹i3 Innovus, Uxbridge, Middlesex, UK, ²Sanofi-Aventis, Bridgewater, UK, ³University of North Carolina at Chapel Hill, Chapel Hill, NC

P-141. Are liver colorectal metastases less responsive to Bevacizumab in female patients? "Gender discrimination" by Bevacizumab or just a sample error?

Aderka D¹, Geva R², Figer A², Beny A³, Hubert A⁴, Klein B⁵, Valianu A¹, Sarely M¹, Ben-Haim M², Catane R¹

¹Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Ramat Gan, Israel, ²Tel Aviv Medical Center, Sackler School of Medicine, Tel Aviv University, ³Rambam Medical Center, Technion School of Medicine, Haifa, ⁴Hadassah Medical Center, The Hebrew University, Jerusalem, ⁵Meir Medical Center, Sackler School of Medicine, Tel Aviv University

P-142. Faecal DNA testing for colorectal cancer: The Norwegian experience

Aloysius T, Lovlie R, Ogreid D, **Parker D**

Nordiag ASA, Bergen, Norway

P-143. 5-Fluorouracil (5-FU),Folinic acid (FA) and Oxaliplatin (FUFOX) as second chemotherapy in patients with metastatic colorectal cancer (MCRC)

Andric Z, Murtezani Z, Kovcin V, Gutovic J, Kostic S

University Clinical Hospital Bezanijska kosa, Belgrade, Serbia

P-144. Faecal occult blood testing detects the majority of interval colorectal cancers in a colonoscopic based surveillance program

Bampton P¹, Sandford J¹, Cole S², Smith A², Morcom J², Young G^{1,2}

¹Flinders Medical Centre, Bedford Park, Australia, ²Repritation General Hospital, Daw Park, Australia

P-145. A phase II study of oxaliplatin (OX), capecitabine (CAP), and bevacizumab (BV) in the treatment of metastatic colorectal cancer

Bendell J¹, Fernando N², Morse M¹, Blobe G¹, Yu D¹, Sutton L¹, Vaccaro G¹, Honeycutt W¹, Franklin A¹, Hurwitz H¹

¹Duke University Medical Center, Durham, NC, ²Georgia Cancer Specialists, USA

P-146. Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors

Bendell J¹, Lager J¹, Zafar Y¹, Yu D¹, George D¹, Nixon A¹, Petros W², Arrowood C¹, Beci R¹, Hurwitz H¹

¹Duke University Medical Center, Durham, NC, ²West Virginia University

P-147. Complete radiological response of colorectal liver metastases (LM) after chemotherapy: Does it mean cure?

Benoist S, Brouquet A, Penna C, Julié C, El Hajjam M, Chagnon S, Emmanuel M, Rougier P, **Nordlinger B**

Ambroise pare Hospital, Boulogne, France

P-148. Changes in first-line chemotherapy do not improve survival in patients with advanced colorectal cancer

Carnaghi C¹, Rimassa L¹, Zuradelli M¹, Morengi E¹, Torri V², Tronconi M¹, Tondulli L¹, Pressiani T¹, Santoro A¹

¹Istituto Clinico Hmanitas, Rozzano, Italy, ²Istituto Ricerche Farmacologiche Mario Negri, Milano, Italy

P-149. Efficacy of bevacizumab plus bolus irinotecan, fluorouracil and leucovorin (IFL-BV) for highly pretreated metastatic colorectal cancer (MCRC).

Carrera S¹, Muñoz A¹, Gil-Negrete A¹, Rubio I¹, Ancizar N¹, Calvo B², Fuente N¹, Barceló R¹, Janhi M¹, López-Vivanco G¹

¹Medical Oncology Department-Hospital de Cruces, Baracaldo, Spain, ²Molecular Biology Laboratory-Hospital de Cruces

P-150. Panitumumab activity in metastatic colorectal cancer patients with \geq 10% epidermal growth factor receptor levels

Chan E¹, Neubauer M², Swanson P³, Harker W⁴, Burris H⁵, Hecht J⁶, Navale L⁷, Brown J⁷, Amado R⁷
¹Vanderbilt Medical Center, Nashville, TN, USA, ²Kansas City Cancer Center, Overland Park, KS, USA,
³Hematology Oncology Associates, Port St. Lucie, FL, USA, ⁴Utah Cancer Specialists, Salt Lake City, UT,
USA, ⁵Tennessee Oncology, Nashville, TN, USA, ⁶UCLA School of Medicine, Los Angeles, CA, USA,
⁷Amgen Inc., Thousand Oaks, CA, USA

P-151. Mismatch repair gene expressions in Amsterdam Criteria II-positive kindreds in Taiwanese population and their relation to clinical features

Chiang J¹, Chen J², Chang Chien C¹, Hsieh P¹
¹Chang Gung Memorial Hospital, Tao Yuan, Taiwan, ²Division of Cancer Research, National Health Research

P-152. Long time survival in patients with colorectal metastasis: Beyond anedoctal experience?

Ciferri E, Castagnola M, Municinò O, Malvezzi E, Bondanza G
U.O. Chirurgia, Genoa -North Hospital , Genoa, Italy

P-153. Effect of folate and a-lipoic acid supplementation on rectal mucosal cell kinetics

Di Marco M, Di Cicilia R, Di Battista M, Brandi G, Palmerini E, Derenzini E, Poggi R, Fanello S, Astorino M, Biasco G
Ins of Hematology and Medical Oncology, Bologna, Italy

P-154. Capecitabine versus 5FU in association with Oxaliplatin or CPT11 in metastatic colorectal carcinoma (MCRC) patients: Compliance and toxicity.

Di Seri M, Ricciardi S, Messina C, Rossi L, Rosati S, Spalletta B, Cerbone L, Russillo M, Manna A, Inigo F
Department of Experimental Medicine and Pathology, University 'La Sapienza', Rome - Italy

P-155. Effects of nutritional support in patients with colorectal cancer during chemotherapy

Dobrila-Dintinjana R¹, Bagic Z¹, Djiaplo I¹, Dintinjana M², Stimac D¹
¹Clinical Hospital Center Rijeka, Internal Clinic, Gastroenterology dpt, Rijeka , Croatia, ²Private Practice Ambulance

P-156. Bevacizumab with chemotherapy for the first-line treatment of metastatic colorectal cancer: "NCI Slovakia" results

Dolinsky J, Salek T, Hlavata Z, Ivancova H, Risnyovszka Z, Mardiak J, Koza I
National Cancer Institute, Bratislava, Slovakia

P-157. Phase II study of celecoxib, Irinotecan, and capecitabine in patients with advanced colorectal cancer

El-Rayes B¹, Shields A¹, Zalupski M², **Bekaii-Saab T**³, Heilbrun L¹, Vaishampayan U¹, Manza S¹, P. A. P¹
¹Karmanos Cancer Center, Dearborn, USA, ²University of Michigan, Detroit, USA, ³Ohio State University, Ohio

P-158. The impact of the ratio of metastatic to examined lymph node on survival in colorectal cancer

El-Zahabi L, Hatoum H, Rashid K, Yassine H, **Shamseddine A**
American University of Beirut Medical Center , Beirut, Lebanon

P-159. Bevacizumab plus oxaliplatin (LOHP), leukovorin (LV)/5-fluorouracil (5-FU) (FOLFOX4) as first line treatment of patients with metastatic colorectal cancer (MCC)

Emmanouilides C¹, Sfakiotaki G², Souglakos J², Mavroudis D², Androulakis N², Kavlaki A², Kotsakis A², Diamandidou E¹, Touroutoglou N¹, Georgoulis V¹
¹Interbalkan Medical Center, Pylaia, Thessaloniki, Greece, ²University Hospital of Herakleion, Herakleion, Greece

P-160. To planning an evidence-based organization for colorectal cancer screening: An Italian experience

Federici A, Barca A, Valle S, Baiocchi D, Quadrino F, Borgia P, Giorgi Rossi P, Guasticchi G
Agency for Public Health, Lazio Region, Rome, Italy

P-161. The XELOX-EL regimen is effective and safe regimen in metastatic colorectal cancer in elderly patients (> 70y): A single center phase II trial.

Geurs F¹, Ponette S¹, Ponette J¹, Kempeneers I¹, Itterbeek P¹, Vandenhove J¹, Vandesteen O², Simmilon A¹

¹Sint Mariaziekenhuis, Halle, BELGIUM, ²SANOFI-AVENTIS, Belgium

P-162. Capecitabine (X) is feasible, effective and well tolerated as long-term first-line treatment for patients (pts) with metastatic colorectal cancer (MCRC) with no access to specialized cancer centers

Giacomi N¹, Fein L², Kaen L³, Nouche G⁴

¹Breast Clinic, La Plata, Buenos Aires, Argentina, ²Clínica de Oncología de Rosario, Santa Fe, Argentina, ³Hospital Vera Barros, La Rioja, Argentina, ⁴Clínica Avellaneda, Avellaneda, Buenos Aires, Argentina

P-163. Postoperative adjuvant chemotherapy (AC) for completely resected hepatic (HM) and/or pulmonary metastases (PM) from colorectal cancer (CRC).

Gil-Negrete A¹, Rubio I¹, Carrera S¹, Barceló R¹, Sancho A¹, Ferreira J¹, Viteri A¹, Calvo B², Muñoz A¹, López-Vivanco G

¹Medical Oncology Department-Hospital de Cruces, Baracaldo, Spain, ²Molecular Biology Laboratory-Hospital de Cruces

P-164. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma. Retrospective comparison.

Gluzman A^{1,2}, Rubinov K¹, Man S^{1,2}, Lavrenkov K^{1,2}, Ariad S^{1,2}

¹Department of Oncology, Soroka University Medical Center, Israel, ²Ben-Gurion University of Negev, Beer-Sheva, Israel

P-165. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical tolerability to fluoropyrimidine-based chemotherapy?

Gusella M¹, Crepaldi G¹, Bolzonella C¹, Ruzzante G¹, Bononi A¹, Padrini R², Ferrazzi E¹

¹IOV Veneto- Ospedale civile di Rovigo Italy, Rovigo, Italy, ²Università di Padova-Italy, Rovigo, Italy

P-166. Pharmacokinetics of 5,10-methylenetetrahydrofolate administered as a 2-hour infusion

Gustavsson B¹, Odin E¹, Spears C², Radulovic S³, Susnjar S³, Charney M⁴, Cantwell M⁴, Robbins J⁴

¹Göteborg University, Göteborg, Sweden, ²Mercy General, Sacramento, CA USA, ³Institute for Oncology and Radiology, Belgrade, Serbia and Montenegro, ⁴Adventrx Pharmaceuticals, Inc. San Diego, CA USA

P-167. The prognostic implications of mucinous type colorectal adenocarcinoma

Hatoum H, El-Zahabi L, Abdel-Khalik Z, Yassine H, Shamseddine A

American University of Beirut Medical Center - Beirut, Lebanon

P-168. Predictive parameters for correlations between the histological type and endoscopic view in large bowel polyps: A study in a south-west region of Romania

Iordache S, Saftoiu A, Gheonea D, Cazacu S, Ciurea T

Clinical Emergency Hospital, Gastroenterology Department, Craiova, Romania

P-169. Peripheral neuropathy - important problem during therapy of colon cancer patients.

Jagiello-Gruszfeld A, Wachula E, Czerniawska M, Zbrzezniak J, Szablowska-Siwik S

ZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii, Olsztyn, Poland

P-170. Capecitabine and oxaliplatin (Xelox) as first line treatment for patients with metastatic colorectal cancer (MCRC)

Karacetin D, Maral O, Yalcın B, Okten B, Incekara O

Sisli Etfal Hospital, Istanbul, Turkey

P-171. First-line treatment with infusional 5-FU, leucovorin, and irinotecan plus bevacizumab (FOLFIRI-B) for metastatic colorectal cancer (mCRC): Preliminary results of a phase II trial

Kopetz S, Glover K, Eng C, Adinin R, Morris J, Wolff R, Lin E, Chang D, Abbruzzese J, Hoff P

MD Anderson Cancer Center, Houston, TX, USA

P-172. Change of blood sedimentation rate characteristics of the patients with gastric, colon and rectal cancer.

Kozlova N¹, Gubin D²

¹Khanty- Mansiysk, Yugra State, Russian Federation, ²Tyumen, Russian Federation

P-173. Colorectal cancer in Kosovo 1999-2004: Epidemiology and treatment experience

Krasniqi A¹, Limani D¹, Hoxha F¹, Mustafa A², Qehaja N², Sopa R², Bicaj B¹, Krasniqi S³, Musa R¹, Luci L²
¹University Clinical Centre of Kosovo; ²Department of Surgery, ³Institute of Pathology, Prishtina, ³National Institute of Public Health Prishtina

P-174. Sensitivity and specificity of immunochemical FOBT for detecting colonic neoplasia

Levi Z, Chazazi R, Vilkin A, Rozen P, Waked A, maoz E, Birkenfeld S, Niv Y
Rabin Medical Center, Beilinson Hospital, Tel Aviv University, Tel Aviv, Israel

P-175. Treatment of elderly patients with metastatic colorectal cancer (MCRC): Our experience.

longo f, proietti e, raimondi c, graziano v, zivi a, sacco p, cerbone l, russillo m, restuccia m, di seri m
Department of Experimental Medicine and Pathology, University 'La Sapienza', Rome - Italy

P-176. Multi-center phase II study of irinotecan + 5-FU/l-LV (RPMI) chemotherapy for patients with metastatic colorectal cancer (OGSG0201)

Mishima H^{1,9}, Ikenaga M^{1,9}, Ishida H^{2,9}, Iwamoto S^{3,9}, Morimoto T^{4,9}, Narahara H^{5,9}, Kato T^{6,9}, Tsujinaka T^{1,9}, Furukawa H^{7,9}, Taguchi T^{8,9}

¹Department of Surgery, Osaka National Hospital, Osaka, Japan, ²Department of Surgery, Osaka Seamens Insurance Hospital, Osaka, Japan, ³Department of Surgery, Kansai Medical University, Osaka, Japan, ⁴Department of Surgery, Yao City Hospital, Osaka, Japan, ⁵Department of Clinical Oncology, Graduate School of Biomedical Science, Hiroshima University, Hiroshima, Japan, ⁶Department of Surgery, Mino City Hospital, Osaka, Japan, ⁷Department of Surgery, Sakai City Hospital, Osaka, Japan, ⁸Japan Society for Cancer Chemotherapy, Osaka, Japan, ⁹Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG), Japan

P-177. Detection of methylated DNA in plasma from colorectal cancer patients and controls by real-time PCR analysis of septin-9

Model F¹, DeVos T¹, Tetzner R², Schuster M², Lesche R², Sledziewski A¹, Day R¹, Lofton-Day C¹
¹Epigenomics, Inc, Seattle, USA, ²Epigenomics AG

P-178. Activity and safety of two different doses of exaliplatin (OX) plus capecitabine (CAP) as first-line treatment for advanced colorectal cancer (CRC)

Moreno I¹, Ibeas-Rollán R¹, Monzo M², Martínez F¹, Moreno J¹, Pou E¹, Hernández R¹, Gel B², Ortigosa S¹, Cuenca A¹

¹Hospital Municipal de Badalona, Badalona, Spain, ²Dpt. Anatomía. Facultad de Medicina. Universidad de Barcelona, Barcelona, Spain

P-179. A single institution experience with hepatic arterial infusion (HAI) of oxaliplatin followed by l-folinic acid modulated continuous HAI of 5-fluorouracil with or without cetuximab for the treatment of stage IV colorectal cancer limited to the liver

Neyns B, Van Nieuwenhove Y, Aerts M, Vandenbroucke F, Delvaux G, De Greve J
Oncology Center, Vrije Universiteit Brussel, Brussels, Belgium

P-180. Colo-rectal carcinoma in a Tropical African setting -The Uganada experience.

Noah M, William O
Mulago National Referral Hospital, Kampala, Uganda

P-181. Patient preference in adjuvant chemotherapy for colorectal cancer

Nolan L, O'Callaghan A, Watkinson K
St Mary's Hospital, Portsmouth, United Kingdom

P-182. Assessment of the efficacy of high risk ("Two Week Wait") referral criteria for colorectal cancer detection

Opaluwa A, Dikki P, Cole J, Steward M, Blunt M, Cullen P
The Queen Elizabeth Hospital

P-183. Influence of VEGF expression on response to therapy with EGFR inhibitor in patients with EGFR negative liver metastases from colorectal carcinoma

Petrovic Z¹, Tarabar D¹, Doder R¹, Tasic O², Tufegdžić I²
¹Dept. of GI Oncology, Clinic of gastroenterology, VMA, ²Institut for Pathology, VMA

P-184. Endoscopic miniprobe ultrasonography in the diagnosis of carcinomas and submucosal tumors of the large intestine

Pinghong Z¹, Liqing Y, Xinyu Q

¹Zhongshan hospital,Fudan University,Shanghai,China, ²Zhongshan hospital,Fudan University,Shanghai,China, ³Zhongshan hospital,Fudan University,Shanghai,China

P-185. Maintenance immunotherapy with low-dose of interleukin-2 (IL-2) and 13-cis-retinoic acid (RA) in patients with metastatic colorectal cancer (MCRC) showing a clinical benefit (CB) from chemotherapy: Results of a multicenter phase II study

Recchia F¹⁻², Saggio G¹, Amiconi G¹, Di Blasio A¹, Cesta A¹, Candeloro G¹, Nuzzo A³, Lalli A⁴, Lombardo M⁵, Rea S⁶⁻²

¹Oncologia, Ospedale Civile di Avezzano, ²Fondazione Carlo Ferri, Monterotondo, ³Oncologia, Ospedale Civile di Lanciano, ⁴Oncologia, Ospedale Civile di Giulianova, ⁵Oncologia, Ospedale Civile di Pescara, ⁶Chirurgia Oncologica, Università degli studi de L'Aquila

P-186. Response to second line treatment following 5,10-methylenetetrahydrofolic acid with 5-fluorouracil as first line treatment in metastatic colorectal cancer

Reid T¹, Spears C², Subramanian M³, Pawl L⁴, Jankovic G⁵, Jelic S⁶, Milinic N⁷, Muzikravic L⁸, Stewart J⁹, Robbins J⁹

¹UCSD and VASDHS, San Diego, CA, USA, ²Mercy General, Sacramento, CA, USA, ³First Dynamic Healthcare Services, Waco, TX, USA, ⁴Spectrum Health, Grand Rapids, MI, USA, ⁵Clinical Centre of Serbia, Belgrade, Serbia and Montenegro, ⁶Institute for Oncology and Radiology,Belgrade, Serbia and Montenegro, ⁷CHC Bezanijaska Kosa, Belgrade, Serbia and Montenegro, ⁸Institute for Oncology Sremska Kamenica, Sremska Kamenica, Serbia and Montenegro, ⁹Adventrx Pharmaceuticals, Inc., San Diego, CA, USA

P-187. Hyperhomocysteinemia, folate deficiency, and carcinogenesis in IBD patients.

Roblin X¹, Phelip J¹, Bonaz B¹, Ducros V²

¹Department of Gastroenterology, CHU Grenoble, Grenoble, France, ²Department of Biology, CHU Grenoble, Grenoble, France

P-188. Activity of cetuximab in patients with colorectal cancer refractory to both-irinotecan and 5-fluorouracil.The first NCIS experience.

Salek T, Hlavata Z, Sufliarsky J, Mardiak J, Dolinsky J, Reckova M
National Cancer Institute,Bratislava,Slovak Republic

P-189. Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a phase I-II study.

santomaggio a¹, morelli m², calista f³, cannita k¹, porzio g¹, rispoli a¹, mancini m¹, marchetti p¹, ficorella c¹, ricevuto e¹

¹University of L'Aquila-Italy, ²IDI-Roma-Italy, ³Cattolica Del Sacro Cuore University (CB)-Italy, ⁴University of L'Aquila-Italy, ⁵University of L'Aquila-Italy, ⁶University of L'Aquila-Italy, ⁷University of L'Aquila-Italy, ⁸University of L'Aquila-Italy, ⁹University of L'Aquila-Italy, ¹⁰University of L'Aquila-Italy

P-190. Influence of bevacizumab on the plasma disposition of CPT 11 and its metabolites in advanced colorectal cancer patients

Schüller J¹, Czejka M², Kiss A², Krexner E¹, Aigner K¹

¹Hospital Rudolfstiftung, Vienna, Austria, ²University Vienna, Austria

P-191. Internal radiation treatment of liver metastases from colorectal cancer with concomitant systemic radiosensitising chemotherapy

Sharma R¹, van Hazel G², Blanshard K³, Price D², Bower G², Shannon J⁴, Gibbs P⁵, Berry D³, Morgan B³, Steward W³

¹Royal Marsden Hospital, London, England, ²Mount Medical Centre, Perth Oncology, Australia, ³University Hospitals of Leicester, UK, ⁴Nepean Hospital, Sydney, Australia, ⁵Royal Melbourne Hospital, Melbourne, Australia

P-192. The prognosis of primary cecal lymphoma

Sin J¹, Jo H, Park K

¹Inje University, Pusan Paik Hospital,Pusan, Korea, ²Pusan National University Hospital,Pusan,Korea, ³Donga University, Pusan, Korea

P-193. Carcinoembryonic antigen (CEA) follow-up of colorectal cancer (CRC) patients after adjuvant treatment

Spratlin J, Hui D, Hanson J, Butts C, Au H
Cross Cancer Institute, Edmonton, Canada

P-194. First line chemotherapy options in metastatic colorectal cancer

Stanculeanu D, Matache R, Minea L, Cringeanu A, Anghel R
Institute of oncology Bucharest

P-195. Combined systemic and local immuno-chemotherapy improves outcome of systemic chemotherapy in treatment of unresectable colorectal liver metastases

Tarabar D, Petrovic Z, Brocic T, Doder R
Military Medical Academy, Belgrade, Serbia

P-196. Fecal Tumor M2-PK - a sensitive and practical non-invasive biomarker for early detection of colorectal cancer

Tonus C¹, Neupert G², Sellinger M³
¹Herz-Jesu-Hospital, Surgical Clinic, 36039 Fulda, Germany, ²Offenbach Municipal Hospital, Surgical Clinic, 63069 Offenbach, Germany, ³Medical Practice for Gastroenterology & Hepatology, 67065 Ludwigshafen, Germany

P-197. Geriatrician activity in a gastro intestinal oncology department in an academic hospital

Tristan C¹, Emmanuel M², Sophie M¹, Laurent T¹, Philippe R²
¹Hôpital Ambroise Paré, Service de Médecine Gériatrique, Boulogne, France, ²Hôpital Ambroise Paré, Service d'hépto-gastro-entérologie et oncologie digestive

P-198. Value of histology in identifying Lynch Syndrome among colorectal cancer patients diagnosed between 50 and 60 years of age

Truta B¹, Chen Y¹, Bianco A¹, Conrad P¹, Guoren D², Velayos F¹, Weinberg V¹, Sleisenger M², Kim Y², Terdiman J¹
¹University California San Francisco, San Francisco, United States, ²Veterans Affairs Medical Center San Francisco, San Francisco, United States

P-199. Methodological quality and reporting of ethical requirements in phase III cancer trials.

Tuech J¹, Pessaux P², Moutel g³, Lefebure B¹, Bridoux V¹, Hervé C³
¹University Hospital Rouen France, ²University Hospital Angers France, ³Laboratoire Ethique Université Paris V

P-200. The correlation of plasma CEA,LDH levels,hemoglobin levels,number of leukocytes,thrombocytes with prognostic factors in colorectal cancer

tuhta a¹, gönüllü g², yücel i²
¹ondokuz mayıs university,department of internal medicine, Samsun, Turkey, ²ondokuz mayıs university,department of medical oncology

P-201. Factor VIII, von Willebrand factor in colorectal cancer

tuhta a¹, yücel i², gönüllü g²
¹Ondokuz Mayıs University, Department of Internal Medicine, Samsun, Turkey, ²Ondokuz Mayıs University,Department of Medical Oncology

P-202. Use of full covered self-expandable metallic stents (SEMS) for the treatment of anastomotic rectal leakage.

vitale m, Villotti G, d'Alba L, Iacopini F, Iacopini G
Gastroenterology and Endoscopy Unit Azienda Ospedaliera San Giovanni-Addolorata

P-203. XELOX is a more well-tolerated chemotherapeutic regimen than FOLFOX 4 for Chinese colorectal cancer patients

Yau T, Chan P, Leung A, Tsang J, Liang R, Epstein R
The University of Hong Kong

P-204. The efficiency of FOLFOX and XELOX application as a first-line chemotherapy of the advanced colorectal cancer patients

Zeynalov R, Musayev I, Gasanzadeh J, Ahadova N, Dadasheva N

Oncological Research Center, Baku, Azerbaijan

P-205. CT perfusion (CTp) for the monitoring of neo-adjuvant chemoradiation therapy in rectal cancer

Petralia G¹, Funicelli L¹, D'andrea G², Sonzogni A¹, Bellomi M¹⁻²

¹European Institute of Oncology, Milano, Italy, ²School of Medicine, Università degli Studi di Milano, Milano, Italy

P-206. Large section histopathology of colorectal tumors in clinical practice

Tot T

Department of Pathology, Central Hospital Falun

P-207. Outcome of acutely perforated colorectal cancers: Experience of a single district general hospital

Anwar M¹, D'Souza F¹, Coulter R¹, Memon B², Khan I¹, Memon M¹

¹Whiston Hospital, Prescot, Merseyside, England, ²Private Clinic, Darwen, Lancashire, England

P-208. Curative treatment to peritoneal carcinomatosis from colorectal origin

Bereeder J, Bernard J, Karimjee B, Benchimol D, Bourgeon A

University Hospital Archet Nice, France

P-209. Feasibility of metastasectomy after bevacizumab and chemotherapy in mCRC - Preliminary results from First BEAT

DiBartolomeo M¹, Van Cutsem E², Michael M³, Kretschmar A⁴, Berry S⁵, Rivera F⁶, Mazier M⁷, Lutiger B⁸, Cunningham D⁹

¹Istituto Nazionale Tumori, Milano, Italy, ²University Hospital Gasthuisberg, Leuven, Belgium, ³Peter MacCallum Cancer Institute, East Melbourne, Australia, ⁴HELIOS-Klinikum, Berlin, Germany, ⁵Sunnybrook Regional Cancer Centre, Toronto, ON, Canada, ⁶Hospital Marqués de Valdecilla, Santander, Spain, ⁷Parexel, Paris, France; F. Hoffmann-La Roche Ltd, Basel, ⁸F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁹Royal Marsden Hospital, Sutton, United Kingdom

P-210. Intraoperative colonoscopy in the management of stenotic colorectal cancer

Khalfalla M, Osmam M

Ain Shams University, Makkah, Saudi Arabia

P-211. Does the tumor down-staging by preoperative chemoradiation of rectal cancer predict the prognosis?

Lee S¹, Lee K¹, Choi J¹, Kim Y²

¹Department of Surgery, Kyunghee University, Seoul, South Korea, ²Department of Pathology, Kyunghee University, Seoul, South Korea

P-212. Soft tissue tumor - a challenging differential diagnosis for surgeons

Leinung S¹, Würfl P, Möbius C, Leinung S, Hauss J

¹Surgical Clinic II, University of Leipzig, ²Surgical Clinic II, University of Ulm, ³Surgical Clinic II, University of Leipzig, ⁴Surgical Clinic II, University of Leipzig, ⁵Surgical Clinic II, University of Leipzig

P-213. Predictors of cure for pelvic recurrence of rectal cancer

Maetani S¹, Nishikawa T¹, Onodera H²

¹Tenri Institute of Medical Research, Tenri, Japan, ²St. Lukes International Hospital, Tokyo, Japan

P-214. Disposable colon intubator with drain and irrigator - alternative to colostomy

Matasov S, Borisova A

RD Center CONTRA CANCRUM COLI

P-215. The management of radiation proctitis due to therapy for anorectal and pelvic malignancies

Mazis A, Orphanotis G, Rathosis S, Spiliopoulos K, Kolimpianakis M, Kotsikoris G

St Andrew General Hospital, Patras, Greece

P-216. Incurable stenosing colorectal carcinoma - endoscopic stent implantation or palliative surgery?

Meyer L^{1,3}, Ptok H^{2,3}, Bereuter M³, Schmidt U⁴, Gastinger I^{1,3}, Lippert H^{2,3}, Meyer F^{2,3}

¹Department of Surgery, Carl Thiem Hospital, Cottbus, Germany, ²Department of Surgery, University Hospital, Magdeburg, Germany, ³Institute for Quality Control in Operative Medicine, University Hospital, Magdeburg, Germany, ⁴StatConsult, Magdeburg, Germany

P-217. Metastasized colorectal carcinoma - is there a place for a lung laser metastasectomy?

Pereszlenyi A, Bis B, Baier B, Schilling A, Rudek B, Rolle A
Centre of Pneumology, Thoracic and Vascular Surgery

P-218. Sentinel lymph node mapping in 118 colorectal cancer : For which reasons ?

Pocard M^{1,2}, Liberale G², Boige V², Duvillard P², Farkhondeh F², Malka D², Ducreux M², Lasser P²
¹Lariboisière Hospital, Paris, France, ²Gustave Roussy Institute, Villejuif, France

P-219. Prognostic effect of sentinel node biopsy in colon carcinoma

Pol R¹, Braat D², Moll F², de vries H², Oosterhuis W²
¹Deventer ziekenhuis, The Netherlands, ²Isala klinieken, locatie Sophia, The Netherlands

P-220. Non-randomised comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases; a prospective study.

Ruers T¹, Joosten J¹, Wiering B¹, Dekker H², Oyen W³, Wobbes T¹, Krabbe P⁴, Punt K⁵
¹Dept. Surgery, Radboud University Medical Centre Nijmegen, Netherlands, ²Det Radiology, Radboud University Medical Centre Nijmegen, ³Dept Nuclear Medicine, Radboud University Medical Centre Nijmegen, ⁴Dept MTA, Radboud University Medical Centre Nijmegen, ⁵Dept. Medical Oncology, Radboud University Medical Centre Nijmegen

P-221. Relationships between yTNM and prognosis in advanced rectal cancer.

Staudacher C, Di Palo S, Tamburini A, Vignali A, Orsenigo E
San Raffaele Scientific Institute. Department of Surgery. University Vita-Salute San Raffaele, Milan, Italy

P-222. Expansion in high dependency units has reduced adverse events for patients who die of colorectal cancer under surgical care in Scotland.

Young J¹, Kerr L², Burton H², Thompson A¹, Stonebridge P³
¹Department of Surgery and Molecular Oncology, UNiversity of Dundee, Ninewells Hospital Dundee, DD1 9SY, ²Scottish Audit of Surgical Mortality, 2nd floor Cirrus Building, Marchburn Drive, Paisley, PA3 2SJ., ³Institute for cardiovascular Research, Ninewells Hospital Dundee, DD1 9SY

P-223. Biocompatibility aspects of Nitinol self-expanding esophageal stents

Alach E¹, **Bonicatto S**¹, Iasi R², Troncoso E¹, Caravelli V², Toloy H², Barbero A¹, Lavezzaro M¹, Mainella A¹
¹San Roque Hospital, Gonnet, Argentina, ²Universidad Tecnológica Nacional, La Plata, Argentina

P-224. Concurrent radiochemotherapy for esophageal cancer in elderly patients

Anghel R, Minea L, Tarlea A, Isacu I, Bacinschi X, Oprea L, Negrei C, Gheta C, Stanculeanu D
Oncological Institute of Bucharest, Bucharest, Romania

P-225. p53 accumulation and COX-2 expression in esophageal squamous cell carcinoma (ESCC) and esophagitis to understand the development of esophageal cancer in Iran

Biramijamal F¹, Iravanloo G², Tahmasebi A³, Fereidooni F², Mirmoemeni M³
¹NIGEB, National Institute for Genetic Engineering & Biochemistry, ²Cancer Institute, Tehran-Iran, ³Razi University, Kermanshah -Iran

P-226. Robot-assisted thoracoscopic esophago-lymphadenectomy for esophageal cancer

Boone J, Draaisma W, Broeders I, Giezeman M, Borel Rinkes I, van Hillegersberg R
University Medical Center Utrecht, Utrecht, the Netherlands

P-227. Adjuvant chemo-radiotherapy in resected esophageal carcinoma

Elez M¹, Galán M¹, Martínez M¹, Laquente B¹, Pérez X¹, Cambray M¹, Boladeras A¹, Farran L², Germà J¹
¹Institut Català D'Oncologia (Hospital Duran i Reynals), ²Hospital Universitari de Bellvitge

P-228. Neoadjuvant treatment of esophagus cancer.

Erbol B¹, Zhetkergen A
¹Kazakh Research Institute of Oncology and Radiology , Almaty, Kazakhstan, ²Kazakh Research Institute of Oncology and Radiology

P-229. Expression profile of the interferon regulated protein GBP-2 in squamous cell carcinoma of the esophagus (SCCE).

Guimarães D¹, Paiva G², Olmedo D¹, Souza D¹, Marques C¹, Pinto C³, Hainaut P⁴, Small I¹, Ferreira C¹, Oliveira I²

¹Clinical Research Service, Instituto Nacional do Câncer, Rio de Janeiro, Brazil, ²Department of Pathology, Instituto Nacional do Câncer, Rio de Janeiro, Brazil, ³Department of Surgery, Instituto Nacional do Câncer, Rio de Janeiro, Brazil, ⁴Molecular Carcinogenesis and Biomarkers Group, International Agency for Research on Cancer

P-230. Analysis of cancer recurrence after curative oesophagectomy for oesophageal cancer

Katayama A¹, Mafune K², Tanaka Y³, Takubo K⁴, Tanaka K¹

¹Japan Railway Tokyo General Hospital, Tokyo, Japan, ²International University of Health and Welfare Mita Hospital, Tokyo, Japan, ³Saitama Cancer Center, Saitama, Japan, ⁴Tokyo Institute of Gerontology, Tokyo, Japan

P-231. Magnifying observation of superficial squamous cell carcinoma of the esophagus

Kumagai Y, Iida M, Yamazaki S

Department of Surgery, Ohta Nishinouchi Hospital, Fukushima, Japan

P-232. Prognostic significance of blood transfusion in patients with esophageal cancer after chemoradiotherapy

Lim J, Truong P, Joe H

Vancouver Island Cancer Centre, Victoria, Canada

P-233. Phase I/II trial of neoadjuvant continuous infusion 5-fluorouracil (CI-5FU) and escalating doses of oxaliplatin (OXA) given weekly with concurrent radiation (RT) in locally advanced esophageal squamous cell carcinoma (ESCC)

Lorenzen S¹, Hermann K¹, Brücher B¹, Zimmermann F¹, Seroneit T², Röthling N³, Molls M, Peschel C, Siewert J, Lordick F

¹Klinikum rechts der Isar, Technical University of Munich, Germany, ²Sanofi-Aventis GmbH, Berlin, Germany, ³Center for Clinical Studies, Technical University of Munich, Germany

P-234. Nutritional consequences of radiotherapy in esophageal and colorectal cancer patients

Mahdavi R¹, Faramarzy E¹, Mohammadzadeh M², Gaeammaghame J¹

¹Tabriz University of Medical Sciences.Iran, ²Department of Radiotherapy Imam khomeini hospital Tabriz University of Medical Sciences.Iran

P-235. Endoscopic submucosal dissection of early esophageal cancer measuring more than 5 cm (technique of using various devices and radical endoscopic resection)

ogata t¹, takagi m¹, aoki t¹, sumi t¹, kato f¹, suzuki y¹, yasuda y¹, yoneda k¹, tsuchida a², aoki t²

¹Hachioji Medecal Center of Tokyo Medical University, Tokyo, Japan, ²Dept. of 3rd surgery of Tokyo Medical University, Tokyo, Japan

P-236. Percutaneous endoscopic gastrostomy using an ultrathin transnasal fiberscope <for patients with trismus or constriction of the digestive tract>

ogata t¹, takagi m¹, aoki t¹, sumi t¹, kato f¹, yasuda y¹, abe k², miyaoka m², tsuchida a³, aoki t³

¹Gastrointestinal Surgery of Hachioji Medecal Center of Tokyo Medical University, Tokyo, Japan, ²Gastrointestinal Internal Medicine of Hachioji Medecal Center of Tokyo Medical University, Tokyo, Japan, ³Dept. of 3rd surgery of Tokyo Medical University, Tokyo, Japan

P-237. Results of endothoracic endoesophageal pull-through (EEPT) method in the surgery of esophageal cancer

Pirnoazen N, Saidi F

Modares General Hospital, Tehran, Iran

P-238. Post-oesophagectomy weight loss - need for continued nutritional support

Qureshi N, Soon Y, Hallissey M

University Hospitals Birmingham NHS Trust, UK

P-239. The impact of high resolution MRI for determining operability of esophageal cancer

Riddell A, Allum W, Thompson J, Wotherspoon A, Cunningham D, Brown G

The Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, UK

P-240. Endoscopic photodynamic therapy for symptomatic palliation in advanced esophageal cancer

Xu K, Niu L, Guo Z, Zuo J

Guangzhou Fuda Cancer Hospital, Guangzhou, China

P-241. Combination chemotherapy of S-1 and Paclitaxel or Cisplatin for advanced or recurrent gastric cancer

Aoki T, Sumi T, Takagi M, Kato F, Suzuki Y, Yasude Y, Yoneda K, Ogata T

Hachioji Medical Center of Tokyo Medical University

P-242. Tegafur-uracil as palliative chemotherapy in refractory locally advanced or metastatic gastric cancer: a Brazilian single center experience

Beato C, Ismael G, Coradazzi A, Cantarelli A, Andrade A, Passeri C, Prado A, Segalla J

Hospital Amaral Carvalho, Jaú, Brazil

P-243. HtrA1 expression, but not p53 expression, is predictive of response to cisplatin-based chemotherapy in patients (pts) with advanced gastric cancer

Catalano V¹, Baldi A², Staccioli M³, Giordani P¹, Carnevali A³, Baldelli A¹, Rossi D¹, Shridhar V⁴, Mureto P³, Catalano G¹

¹S. Salvatore Hospital, ²Second University of Naples and Regina Elena Cancer, Inst., ³S. Salvatore Hospital,

⁴Mayo Clinic Cancer Center

P-244. Inhibition of N-desulfated heparin on metastasis of orthotopic implantation of human gastric carcinoma

Chen J¹, Chen M, Lu J, Chen W, Zhu J, Chen N, Lu Y, Chen G, Geng J

¹Department of Gastroenterology, Shanghai Sixth People's Hospital, ²Shanghai Sixth People's Hospital,

³Shanghai Sixth People's Hospital, ⁴Shanghai Sixth People's Hospital, ⁵Shanghai Sixth People's Hospital,

⁶Shanghai Sixth People's Hospital, ⁷Shanghai Sixth People's Hospital, ⁸Shanghai Laboratory Animal

Center, Chinese Academy of Sciences, ⁹Shanghai Institute of Cell Biology, Chinese Academy of Sciences

P-245. Surgical treatment for early cancer in the proximal third of the stomach

Chung K, Kim J

Kangnam Sacred Heart Hospital, Hallym University, Seoul, South Korea

P-246. Dose-dense chemotherapy with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A feasibility study

Dalla Chiesa M¹, Tomasello G¹, Buti S¹, Negri F¹, Buononato M², Lazzarelli S¹, Donati G¹

¹Oncology Division, Hospital of Cremona, ²Surgery Division, Hospital of Cremona

P-247. Positron emission tomography (18FDG-PET) in targeted therapy with cetuximab in gastric or gastroesophageal junction (GEJ) adenocarcinoma: First results of the Italian Phase II Study

Di Fabio F¹, Pinto C¹, Fanti S², Rojas Llimpe F¹, Longobardi C¹, Nanni C², Funaioli C¹, Ambrosini V², Sperandi F¹, Martoni A¹

¹Medical Oncology Unit, S.Orsola-Malpighi Hospital, Bologna, Italy, ²Nuclear Medicine Unit, S.Orsola-

Malpighi Hospital, Bologna, Italy

P-248. Gastrointestinal cancers - assessment of pain in elderly patients

Dobriša-Dintinjana R¹, Bagić Z^{1,3}, Djipalo I¹, Dintinjana M², Stimac D¹

¹Clinical Hospital Center Rijeka, Internal Clinic, Gastroenterology dpt, Rijeka, Croatia, ²Private Practice Ambulance

P-249. Clinical and epidemiologic characteristics of patients with upper GI cancers in west Azarbeijan province of Islamic Republic of IRAN 2004-2005.

Entezami H¹, Shakibi A¹, Sheikhi N², Rahmani A², Maleki M²

¹Urmia social security organization, ²Jahad AVE P.O.BOX 1138 Urmia -iran

P-250. Irinotecan plus isovorin and 5-fluorouracil in patients with previously untreated gastric adenocarcinoma.

Gerolymos M, Koutras A, Makatsoris T, Onyenadum A, Iconomou G, Kontogeorgou L, Kalofonos H
Division of Oncology, Department of Medicine, University Hospital, Patras Medical School, Greece

P-251. Folfiri is an active regimen as 2nd line chemotherapy after cisplatin 5-fluorouracil- based chemotherapy in advanced gastric cancer

Giordani P¹, Graziano F², Aitini E³, Catalano V¹, Silva R⁴, Pucci F⁵, Tamperi S⁶, Santini D⁷, Labianca R⁸, Cascinu S⁹

¹Ospedale S. Salvatore, ²Ospedale di Urbino, ³Ospedale C. Poma, ⁴Ospedale Profili, ⁵Az. Ospedaliera di Parma, ⁶Ospedale per gli Infermi, ⁷Università Campus Biomedico, ⁸Ospedali Riuniti, ⁹Università Politecnica delle Marche

P-252. The relation of platelet count and tumor progression in resectable gastric cancer

Gong S¹, Joo J¹

¹Eulji Medical Center, Seoul, South Korea, ²Eulji Medical Center, Seoul, South Korea

P-253. Treatment compliance in gastric cancer patients treated with postoperative radio-chemotherapy

Guzel Z, Szawlowski A

Cancer Centre -Institute Warsaw, Poland

P-254. The pattern of age distribution of different cancers in Babol, the north of Iran

Hajian-Tilaki K, Firouzjahi A, Kia M

Babol University of Medical Sciences, Tabol, Iran

P-255. Epidemiologic aspects of patients with gastric cancer in the north of Iran

Hajian-Tilaki K, Taheri H, Khalili R

Babol University of Medical Sciences, Babol, Iran

P-256. Survival improvements in gastric cancer during recent years in Korea

Han S¹, Jin S¹, Cho Y¹

¹Department of Surgery, School of Medicine, Ajou University, Suwon, Korea, ²Department of Surgery, School of Medicine, Ajou University, Suwon, Korea, ³Department of Surgery, School of Medicine, Ajou University, Suwon, Korea

P-257. Capecitabine (X) + fractionated cisplatin (P) as first-line therapy in patients (pts) with advanced gastric carcinoma (AGC): mature efficacy/safety findings from a large phase II study

Jin M¹, Shen L¹, Hu B², Yu J³, Wen Z⁴, Su Y⁵, Wang B⁶, Chen L⁷, Ying H⁸, Chen L⁹

¹Beijing Cancer Hospital, Beijing, China, ²Anhui Provincial Hospital, Hefei, China, ³No.1 Hospital of Zhejiang Medical University, Hangzhou, China, ⁴Shanghai Changhai Hospital, Shanghai, China, ⁵Jiangsu Provincial People's Hospital, Jiangsu, China, ⁶Jinan Military Command General Hospital, Jinan, China, ⁷No. 1 Hospital of Jiangxi Medical University, Jiangxi, China, ⁸Shanghai Ruijin Hospital, Shanghai, China, ⁹Shangdong Provincial Cancer Hospital, Jinan, China

P-258. Results of surgical treatment of gastric cancer in young patients.

Kolodziejczyk P, Kulig J, Popiela T, Sierzega M, Szczepanik A

Ist Department of Surgery, Jagiellonian University, Krakow, Poland

P-259. Postoperative chemoradiation for resected gastric cancer: Is the MacDonald Regimen tolerable?

Kundel Y¹, Idelevich E², Man S³, Lavrencov K³, Purim O¹, Kovel S⁴, Pfeffer R⁵, Salomon S¹, Sulkes J¹, Brenner B¹

¹Davidoff Cancer center, Rabin Medical Center, Beilinson Campus, Petach -Tiqva, Israel, ²Institute of Oncology, Kaplan Medical Center, Rehovot, Israel, ³Oncology department, Soroka University Medical Center, Beersheva, Israel, ⁴Institute of Oncology, Asaf Harofeh Medical Center, Zifrin, Israel, ⁵Institute of Oncology, Chaim Sheba Medical Center, Telhasomer, Israel

P-260. Comparison of RT-PCR and FISH for detection of MALT1 gene rearrangements in MALT lymphomas involving gastrointestinal tract

Lin P, Konoplev S, Abruzzo L, Medeiros L

M. D. Anderson Cancer Center, Houston, TX, USA

P-261. Sequential treatment with cisplatin (p) in combination with infusional 5-fu/lv (pfl) followed by irinotecan (lr) + 5-fu/lv (lrf) followed by docetaxel (t) + 5-fu/lv (tfl) in patients (pts) with metastatic (m) gastric carcinoma (gc): Preliminary results of a phase II trial by the Gruppo Oncologico Nord-Ovest (G.O.N.O.)

Loupakis F¹, Masi G¹, Fontana E¹, Picone V², Mentuccia L², Granetto C³, Fea E³, Pfanner E⁴, Lencioni M⁴, Falcone A^{1,5}

¹Ospedali Riuniti, Livorno, Italy, ²Policlinico Umberto I, Roma, Italy, ³Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy, ⁴Ospedale S. Chiara, Pisa, Italy, ⁵Università degli studi, Pisa, Italy

P-262. Palliative interventions in surgical patients with gastric carcinoma

Meyer L^{1,3}, Ptok H^{2,3}, Schmidt U⁴, Gastinger I^{1,3}, Lippert H^{2,3}, Meyer F^{2,3}

¹Department of Surgery, Carl Thiem Hospital, Cottbus, Germany, ²Department of Surgery, University Hospital, Magdeburg, Germany, ³Institute for Quality Control in Operative Medicine, University Hospital, Magdeburg, Germany, ⁴StatConsult, Magdeburg, Germany

P-263. Appraisal of validity sentinel lymph node biopsy in gastric carcinoma

Mitrovic N¹, Radovanovic D¹, Stevanovic D¹, Pavlovic I¹, Kosanovic R¹, Jasarovic D¹, Radojevic D¹, Pavlovic A², Tufegdzcic M², Zivanovic J¹

¹Surgical Clinic - Clinical Hospital Centre "dr Dragisa Misovic" Belgrade, ²Department of gastroenterology - Clinical Hospital Centre "dr Dragisa Misovic", Belgrade

P-264. Docetaxel, oxaliplatin and 5-fluorouracil: A phase I, pharmacokinetic and pharmacogenomic study

Mulcahy M¹, Hochster H², Ryan T², Avram M¹, Kolesar J³, Benson A¹

¹Northwestern University, Chicago, USA, ²New York University, New York, United States, ³University of Wisconsin, Madison, United States

P-265. New insights into the pathophysiology of muscle depletion in gastric cancer patients

Muscaritoli M¹, Costelli P², Iannuzzi S¹, Aversa Z¹, Bonetto A², Penna F², Bossola M³, Rossi Fanelli F¹, Baccino F²

¹Dept. of Clinical Medicine, University 'La Sapienza', Rome, Italy, ²Experimental Medicine and Oncology, Univ. of Turin, Turin, Italy, ³Surgery, Catholic University, Rome, Italy

P-266. Gastric cancer with ovarian metastases: Clinicopathological features and surgical treatment

Nered S, Klimenkov A, Stilidi I, Gubina G

N.N.Blokhin Cancer Research Center RAMS, Russian Federation, Moscow

P-267. Patient's self-reported quality of life to predict survival in advanced gastric cancer

Park S, Nam E, Bang S, Cho E, Shin D, Lee J

Hematology and Oncology, Dept of Internal Medicine, Gachon Medical School Gil Me, Incheon, South Korea

P-268. Cetuximab in combination with folfiri as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Preliminary results of the Italian Phase II study

Pinto C¹, Di Fabio F¹, Siena S², Cascinu S³, Rojas Llimpe F¹, Ceccarelli C⁴, Mutri V¹, Giaquinta S¹, Piana E¹, Martoni A¹

¹Medical Oncology Unit, S.Orsola-Malpighi Hospital, Bologna, Italy, ²Medical Oncology Unit, Niguarda Cà Granda Hospital, Milan, Italy, ³Medical Oncology Unit, Torrette Hospital, Ancona, Italy, ⁴Pathology Unit, S.Orsola-Malpighi Hospital, Bologna, Italy

P-269. Weekly infusional 5-fluorouracil and Leucovorin and biweekly Cisplatin, a convenient treatment option in advanced gastric cancer

Purim O¹, Kundel Y¹, Figer A², Stemmer S¹, Sulkes A¹, Brenner B¹

¹Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva and Sackler School Of Medicine Tel Aviv University, Israel, ²Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva and Sackler School Of Medicine Tel Aviv University, Israel, ³Tel-Aviv Souarsky Medical Center Division Of Oncology, Sackler Scholl Of Medicine Tel Aviv University, Israel, ⁴Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva and Sackler School Of Medicine Tel Aviv University, Israel, ⁵Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva and Sackler School Of Medicine Tel Aviv University, Israel, ⁶Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva and Sackler School Of Medicine Tel Aviv University, Israel

P-270. Prophylactic gastrectomy for E-Cadherin (CDH1) mutation carriers: Report of a series

Qureshi N¹, Whiting J¹, Hallissey M¹, Cole T², Mckown C², Gourevitch D¹, Fielding J¹

¹University Hospitals Birmingham NHS Trust, UK, ²West Midlands Regional Genetics Unit, United Kingdom

P-271. Clinical applications of sentinel lymph node biopsy for the staging, treatment and prognosis of gastric cancer

Radovanovic D, Mitrovic N, Stevanovic D, Pavlovic I, Jasarovic D, Kosanovic R, Radojevic D
Surgical Clinic - Clinical hospital Centre ``dr Dragisa Misovic``, Belgrade

P-272. Adjuvant treatment for adenocarcinoma of stomach and oesophago-gastric junction - a Glasgow experience

Sivaramalingam M, MacLaren V, Yosef H
Beatson Oncology Centre, Glasgow, United Kingdom

P-273. Sentinel node identification during laparoscopic gastrectomy for gastric cancer

Staudacher C¹, Orsenigo E¹, Carlucci M¹, Tomajer V¹, Tamburini A¹, Masci E², Albarello L³, Doglioni C³
¹Department of Surgery-San Raffaele Scientific Institute-University Vita-Salute, Milan, Italy, ²Department of Gastroenterology-San Raffaele Scientific Institute-University Vita-Salute, Milan, Italy, ³Department of Pathology-San Raffaele Scientific Institute-University Vita-Salute, Milan Italy

P-274. Laparoscopic distal gastrectomy with regional lymph node dissection for gastric cancer

Tanimura S, Higashino M, Fukunaga Y, Kishida S, Ogata A, Fujiwara Y
Osaka City General Hospital, Osaka, Japan

P-275. Preliminary data on perioperative chemotherapy with Docetaxel, Oxaliplatin and Capecitabine (DOC) in patients with locally advanced unresectable gastric cancer

Viudez A, Rodriguez J, Chopitea A, De la Camara J, Viteri S, Olier C, Reyna C, Garcia-Foncillas J
Clinica Universitaria Navarra, Pamplona, Spain

P-276. Comparing D2 Gastrectomy with D2 Gastrectomy plus chemoradiotherapy as treatment for gastric cancer

WESTON A, VINHOLES J, ANDRADE M, ALMEIDA W
Gastroenterology Institute, Porto Alegre, Brazil

P-277. CD14, but not TLR4 gene polymorphism was associated with helicobacter pylori associated non-cardiac gastric carcinoma in Chinese patients

Xia B¹, Li L¹, Li C², Guo Q¹, Zhou F², Wang Q¹
¹Wuhan University Zhongnan Hospital, Wuhan, China, ²Research Center of Digestive Diseases, Wuhan University, Wuhan, China, ³Research Center of Digestive Diseases, Wuhan University, ⁴Wuhan University Zhongnan Hospital

P-278. Expression of Survivin and EPR-1 protein in gastric carcinoma tissues and its relation to clinicopathological parameters

Xuequan Y
Affiliated Hospital of Nanjing, University of Traditional Chinese Medicine, Nanjing, China

P-279. Chinese jianpi herbal recipe Wei Chang An(WCA) on prognosis of patients with gastric carcinoma-Cox regression analysis of 208 cases

Zhao A¹, Cai Y², Yang J, Zheng J, Shen K
¹Department of Oncology Longhua Hospital, Shanghai University of Traditional Chinese Medicine, China, ²School of Public Health, Shanghai Second Medical University, China

P-280. Navelbine in the treatment of metastatic gastric cancer

Zhavrid E, Sachivko N, Khodina T
Institute of Oncology and Medical Radiology, Minsk, Belarus

P-281. Size does not matter! Patterns of response and progression in patients (pts) with metastatic gastro intestinal stromal tumours (GISTS) on imatinib mesylate (IM)

Bulusu V², Fawcett S¹, Cook N², Hatcher H², Moyle P¹, Carroll N¹, Earl H², Save V³, Hardwick R⁴, Sherbourne K²
¹Addenbrookes Hospital, Dept of Radiology, Cambridge, UK, ²Addenbrookes Hospital, Oncology centre, Cambridge, UK, ³Addenbrookes Hospital, Dept of Pathology, Cambridge UK, ⁴Addenbrookes Hospital, Dept of Surgery, Cambridge, UK

P-282. Chemotherapy in patients with nonresectable cancer of the biliary system or advanced gall-bladder cancer : Do elderly have benefit at all?

Dobrila-Dintinjana R¹, Bagic Z¹, Djipalo I¹, Dintinjana M⁴, Stimac D¹

¹Clinical Hospital Center Rijeka, Internal Clinic, Gastroenterology dpt , Rijeka, Croatia, ⁴Private Practice Ambulance Rijeka, Rijeka, Croatia

P-283. Sunitinib in Japanese patients with GIST after prior treatment with imatinib mesylate: A phase I/II dose-escalation study

Doi T¹, Shirao K², Yamada Y², Muro K², Fuse N¹, Euda E³, Li Y³, Togo K³, Baum C⁴, Ohtsu A¹

¹National Cancer Center Hospital East, ²National Cancer Center Hospital, ³Pfizer Japan Inc., ⁴Pfizer Inc.

P-284. Clinical outcome after stereotactic body radiation therapy of unresectable Klatskin tumors

Ernst I¹, Luecking P¹, Beckers E¹, Eickmeyer F², Fiedler V², Schulz U¹

¹Klinikum, dep.Radiation Oncology, Krefeld, Germany, ²Klinikum, dep.Diagnostic Radiology, Krefeld, Germany

P-285. Pathological, radiological and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate: a review of 37 cases.

Goh B¹, Chow P¹, Chuah K², Yap W², Foo K³, Wong W¹

¹Dept of Surgery, Singapore General Hospital, Singapore, ²Dept of Pathology, Singapore General Hospital, Singapore, ³Dept of Medical Oncology, National Cancer Centre, Singapore

P-286. Sunitinib treatment in pediatric patients with metastatic GIST following failure of imatinib

Janeway K¹, Matthews D², Butrynski J³, D'Amato G⁴, Agresta S⁴, Garrett C⁴, Corless C⁵, Albritton K⁶, Demetri G⁶

¹Dana-Farber Cancer Institute and Children's Hospital, ²Children's Hospital and Regional Medical Center and University of Washington, ³Seattle Cancer Care Alliance and University of Washington, ⁴H Lee Moffitt Cancer Center and Research Institute, ⁵Oregon Health and Science University Cancer Institute, ⁶Dana-Farber Cancer Institute

P-287. Gastrointestinal stromal tumors of the stomach - surgical therapy and early postoperative outcome

Meyer L^{1,3}, Ptok H^{2,3}, Schmidt U⁴, Gastinger I^{1,3}, Lippert H^{2,3}, Meyer F^{2,3}

¹Department of Surgery, Carl Thiem Hospital, Cottbus, Germany, ²Department of Surgery, University Hospital, Magdeburg, Germany, ³Institute for Quality Control in Operative Medicine, University Hospital, Magdeburg, Germany, ⁴StatConsult, Magdeburg, Germany

P-288. Impact of concomitant chemoradiation therapy for T1-T2 anal canal carcinoma

Peignaux K¹, Azria D², Zouhair A³, Lorchel F⁴, Truc G¹, Chauffert B¹, Créhange G¹, Bosset J⁴, Maingon P¹

¹Centre Georges-François Leclerc, Dijon , France, ²Centre Val d'Aurelle, France, ³Centre Hospitalier Universitaire Vaudois, France, ⁴Centre Hospitalier Universitaire Minjoz, France

P-289. External beam radiotherapy with capecitabine in locally advanced gallbladder carcinoma:

Does it improve the outcome?

Rastogi N¹, Rawat R¹, Saraswat V², Chouldhuri G², Ravi N²

¹Dept. of Radiotherapy, Sanjay Gandhi, PGIMS, Lucknow, India, ²Dept. of Gastroenterology, Sanjay Gandhi, PGIMS, Lucknow, India

P-290. PET imaging demonstrates two patterns of response in GIST patients benefiting from long-term sunitinib therapy

Raut C¹, Van den Abbeele A¹, Ramaiya N¹, Morgan J², George S², Quigley M², Dollard A², Bertagnolli M¹, Baum C³, Demetri G²

¹Dana-Farber Cancer Institute and Brigham & Women's Hospital, ²Dana-Farber Cancer Institute, ³Pfizer Global Research and Development

P-291. Diagnostic and therapeutic strategy for desmoid tumors in association with familial adenomatous polyposis (FAP)

Yoshikawa R^{1,2}, Yanagi H¹, Gega M¹, Gondo N¹, Noda M¹, Fujiwara Y¹, Utsunomiya J², Hashimoto-Tamaoki T^{2,3}, Yamamura T¹

¹Second Department of surgery, Hyogo College of Medicine, Nishinomiya, Hyogo , Japan, ²Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Japan, ³Department of Genetics, Hyogo College of Medicine, Nishinomiya, Japan

P-292. Preliminary results of a phase I study of external beam radiation therapy (EBRT), oxaliplatin (OX), bevacizumab (BV), and capecitabine (CAP) for locally advanced or metastatic adenocarcinoma of the rectum

Bendell J, Czito B, Willett C, Vaccaro G, Morse M, Yu D, Honeycutt W, Franklin A, Hurwitz H
Duke University Medical Center, Durham, NC

P-293. Phase II study of pre-operative cetuximab, 5-fluorouracil and radiotherapy in rectal cancer: Early analysis of toxicity

Bertolini F¹, Zironi S¹, Malavasi N¹, Losi L², Dealis C¹, Bertoni F³, Chiara S⁴, Bengala C¹, Luppi G¹, Conte P¹

¹Department of Oncology, Modena, Italy, ²Section of Pathology, Modena, Italy, ³Section of Radiotherapy, Modena, Italy, ⁴Department of Oncology Genova National Cancer Institute, Genova, Italy

P-294. Systemic chemotherapy as initial treatment for patients with unresectable synchronous metastases from rectal carcinoma: A valid option?

declety g, mitry e, lepere c, bachet j, benoist s, vaillant j, n'gassam s, penna c, nordlinger b, rougier p
hopital Ambroise Pare, boulogne billancourt

P-295. Retrospective analysis of rectal and rectosigmoid carcinoma diagnosed in elderly patients

DINCER S¹, AKBORU M¹, ASKAROGLU B¹, HANCILAR T¹, ISIKLI L¹, DEMIR C², OZKARAGOZ F², UNSAL M¹

¹Okmeydani Training and Research Hospital Department of Radiation Oncology, Istanbul, Turkey, ²Okmeydani Training and Research Hospital Department of Medical Oncology, Istanbul, Turkey

P-296. Preoperative chemoradiation versus radiation alone for resectable rectal adenocarcinoma: The Centre Francois Baclesse experience

Florescu C, Henry-Amar M, Jacob J, Ollivier J, Galais M, Guilloit J, M'Vondo J, Vie B
Centre François Baclesse, Caen, France

P-297. Clinical and histological evaluation of total remissions considering neoadjuvantly treated rectal neoplasms

Gabor M¹, Tibor S¹, Miklos T¹, Istvan B¹, Akos H²

¹Kenezy County Teaching Hospital, General Surgical Dept., Debrecen, Hungary, ²Univ. of Debrecen, School of Med., Dept. of Radiation Oncology

P-298. Excision repair cross-complementing group 1 (ERCC1) gene polymorphism is associated with local toxicity and tumor regression in rectal cancer patients treated with chemoradiation.

Gusella M, Capirci C, **Crepaldi G**, Marinelli R, Bolzonella C, Ferrazzi E
IOV Veneto- Ospedale civile di Rovigo, Rovigo, Italy, Rovigo, Italy

P-299. A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer

Jakobsen A¹, Morstensen J¹, Bisgaard C¹, Lindebjerg J¹, Bendtsen V², Rafaelsen S¹

¹Vejle Hospital, 7100 Vejle, Denmark, ²Slagelse Hospital, 4200 Slagelse, Denmark

P-300. Histopathological assessment of the effect of long course chemoradiation of locally advanced rectal cancer

Lindebjerg J, Jakobsen A, Rafaelsen S, Bisgaard C
Danish Colorectal Cancer Group South, Vejle Hospital, Denmark

P-301. Radiotherapy and anal canal carcinoma. Retrospective analysis.

Martinez A, Bibiloni C, Picasso M, Rafailovici L, Filomia M, Dosoretz B
VIDT Centro Medico, Buenos Aires, Argentina

P-302. Sphincter preservation and pathologic response in rectal cancer undergoing neoadjuvant chemoradiation with and without oxaliplatin according to TS expression

Motlagh A¹, Azadeh P¹, Rajabi B¹, Shafaghi B², Fudazi M⁴, Fazlalizadeh A¹, Valaei N³, Davaei M³

¹Imam Hossien Hospital, Shahid Beheshti University, ²Khtamolanbia Hospital, ³Shahid Beheshti University

P-303. Phase II clinical trial of weekly oxaliplatin plus capecitabine with concurrent preoperative radiotherapy in locally advanced resectable cancer

Navarro M, Majem M
Institut Catala d'Oncologia

P-304. Can all rectal cancer patients older than 70 years be safely treated with neoadjuvant chemoradiotherapy?

Pasetto L¹, Basso U¹, Friso M², Pucciarelli S³, Rugge M⁴, Agostini M³, Serpentine S³, Rossi E¹, Nitti D³, Monfardini S¹

¹Istituto Oncologico Veneto: Oncology Division, Padova, Italy, ²Istituto Oncologico Veneto: Radiotherapy Department, Padova, Italy, ³Istituto Oncologico Veneto: II Surgical Clinic, Padova, Italy, ⁴Istituto Oncologico Veneto: Pathology Division, Padova, Italy

P-305. Patients' preference and involvement in therapeutic decision-making for patients with low rectal cancer and relationship with their current quality of life.

Pocard M^{1,2}, Sideris L², Zenasni F², Vernerey D², Dauchy S², Di Palma M², Lasser P²

¹Lariboisière Hospital - Paris, France, ²Gustave Roussy Institute - Villejuif, France

P-306. Comparison of functional results and quality of life for patients operated for very low rectal cancer with a technique to avoid colostomy: Coloanal anastomosis versus perineal colostomy with colonic muscular graft.

Pocard M^{1,2}, Sideris L², Zenasni F², Vernerey D², Duvillard P², Malka D², Boige V², Lasser P²

¹Lariboisière Hospital, Paris, France, ²Gustave Roussy Institute, Villejuif, France

P-307. Development of bio-imaged guided radiotherapy in rectal cancer

Roels S¹, Slagmolen P², Vandecaveye V³, Depuydt T¹, Strrobants S⁴, Dymarkowski S³, Penninckx F⁵, Haustermans K¹

¹University Hospital Gasthuisberg, Department of Radiation Oncology, Leuven, Belgium, ²University Hospital Gasthuisberg, Medical Image Computing (ESAT/PSI), Faculties of Medicine and Engineering, ³University Hospital Gasthuisberg, Department of Radiology, Leuven, Belgium, ⁴University Hospital Gasthuisberg, Department of Nuclear medicine, Leuven, Belgium, ⁵University Hospital Gasthuisberg, Department of Abdominal Surgery

P-308. The assessment of recurrence in multimodal treated rectal cancer

- retrospective study

Scripcariu V^{1,2}, **Dajbog E**^{1,2}, Letter L^{1,2}, Ferariu D³, Pricop A^{1,2,4}, Negru D⁴, Grigoras M⁴, Volovat C⁵, Drug V⁶, Dragomir C^{1,2}

¹Third Surgical Unit, "St. Spiridon" University Hospital, University of Medicine and Pharmacy, Iasi, Romania, ²Centre of Surgical Oncology (MDT), "St. Spiridon" University Hospital, University of Medicine and Pharmacy, Iasi, Romania, ³Department of Pathology, "St. Spiridon" University Hospital, University of Medicine and Pharmacy, Iasi, Romania, ⁴Department of Radiology, "St. Spiridon" University Hospital, University of Medicine and Pharmacy, Iasi, Romania, ⁵Department of Oncology, "St. Spiridon" University Hospital, University of Medicine and Pharmacy, Iasi, Romania, ⁶Institute of Gastroenterology and Hepatology, "St. Spiridon" University Hospital, University of Medicine and Pharmacy, Iasi, Romania

P-309. Neoadjuvant folfox-4 followed by chemoradiation plus intraoperative electron boost in locally advanced rectal cancer: Long term results

Serrano J, Calvo F, Gomez-Espi M, Garcia R, Ibañez C, Garcia-Alfonso P, Esperanza L, De la Mata M, Arranz J, Rafael H

Gregorio Marañon University Hospital , Madrid, Spain

P-310. 5-year follow up study of neoadjuvant combined therapy for rectal cancers

Tibor S¹, Gabor M¹, Istvan B¹, Akos H²

¹Kenezy County Teaching Hospital, General Surgical Dept., Debrecen, Hungary, ²Department of Radiation Oncology of University of Debrecen

P-311. Chemoradiotherapy for rectal cancer : Relation between tumoral pathological response and nodal status.

Vendrely V¹, Laurent C², Smith D¹, Rullier A³, Rullier E²

¹Service d'onco-radiothérapie, Hôpital Saint André, Bordeaux, France, ²Service de chirurgie viscérale, Hôpital Saint André, Bordeaux, France, ³Service d'anatomo-pathologie, hôpital Pellegrin, Bordeaux, France

P-312. Adjuvant radiochemotherapy of rectal cancer: Patterns of care and analysis of protocol violations

Weissenberger C, Barke A, Gehring V, Müller D, von Plehn G, Henne K

University Hospital of Freiburg, Dept. of Radiotherapy , Freiburg, Germany

P-313. Sexual dysfunction after rectal cancer treatment

Yektatalab S¹, Talei A², Moosavinasab M³

¹Jahrom University of Medical Sciences, Shiraz, Iran, ²Shiraz Medical University, Shiraz, Iran, ³Shiraz Medical University, Shiraz, Iran

P-314. Disclosure of competing financial interests and role of sponsors in phase III cancer trials.

Tuech J¹, Lefebure B¹, Di Fiore F¹, Schraub S², Herve C³

¹Rouen University Hospital, Rouen, France, ²CPS Strasbourg, Germany, ³LEM Paris V

PD-001. Evaluation of quality of life (QoL) in 1210 patients (pts) with metastatic colorectal cancer (MCRC) treated with capecitabine (X) in Brazil: updated findings from a large pt cohort with analysis as a function of pts' ECOG PS

Beato C¹, Van Eyll B², Federico M³, Skare N⁴, Perdicaris M⁵, Franke F⁶, Oliveira C⁷, Cabral S⁸, Ribeiro R⁹, Gampel O¹⁰

¹Hospital Amaral Carvalho, Jaú, SP, Brazil, ²Instituto Do Câncer Arnaldo Vieira Carvalho, Sao Paulo, SP, Brazil, ³Hospital Das Clínicas São Paulo, São Paulo, SP, Brazil, ⁴Hospital Erasto Gaertner -, Curitiba, PR, Brazil, ⁵Hospital Beneficência Portuguesa De Santos, Santos, SP, Brazil, ⁶Hospital De Caridade De Ijuí, SP, Brazil, ⁷Real Benemérita Sociedade Portuguesa Beneficencia, Sao Paulo, SP, Brazil, ⁸Centro De Quimioterapia A. Imunoterapia - Belo Horizonte MG, Brazil, ⁹Hospital Do Câncer - Instituto Do Câncer Do Ceará, Fortaleza, CE, Brazil, ¹⁰Instituto Assistência Médica Servidor Público Estadual, Sao Paulo, SP, Brazil

PD-002. Phase I/II study of docetaxel + folfox in locally advanced or metastatic gastric cancer patients

Filippelli G, Lucia M, La Gattuta G, Caputo A, Olivito V, Talarico R, De Simone R, Dima G

San Francesco di Paola Hospital, Paola, Italy

PD-003. Continuous daily dosing of sunitinib in patients with advanced GIST: Initial results of a phase II study.

George S¹, Casali P², Blay J³, Le Cesne A⁴, Tyler A¹, Quigley M¹, Tassell V⁵, Baum C⁵, Demetri G¹

¹Dana-Farber Cancer Institute, ²Istituto Nazionale Tumori, ³Centre Leon Berard, ⁴Institut Gustave Roussy, ⁵Pfizer Global Research and Development

PD-004. A novel dimorphism and a new missense mutation in exon 20 of the EGFR gene in patients with advanced colorectal cancer

Metzger B¹, Pauly M¹, Faber C², Kayser J², Roman F³, Schmit J³, Dicato M⁴, Berchem G⁴

¹Laboratoire de Recherche sur le Cancer et les Maladies du Sang/ Centre Hospitalier/ L-1210 Luxembourg, ²Service de Chirurgie/ Clinique Ste Thérèse/ L-2763 Luxembourg, ³Laboratoire de Rétrovirologie/ Centre de Recherche Public de la Santé/ L-1526 Luxembourg, ⁴Service d'Hémo-Cancérologie/ Centre Hospitalier/ L-1210 Luxembourg

PD-005. Panitumumab in metastatic colorectal cancer patients with low/negative epidermal growth factor receptor levels

Mitchell E¹, Hecht J², Baranda J³, Malik I⁴, Richards D⁵, Navale L⁶, D'Avirro P⁶, Amado R⁶

¹Thomas Jefferson Medical College, Philadelphia, PA, USA, ²UCLA School Medicine, Los Angeles, CA, USA, ³University of Kansas Medical Center, Kansas City, KS, USA, ⁴Loma Linda Cancer Center, Loma Linda, CA, USA, ⁵Tyler Cancer Center, Tyler, TX, USA, ⁶Amgen Inc., Thousand Oaks, CA, USA

PD-006. Cisplatin-based combined modality therapy for anal carcinoma: Long-term results

Olivatto L, Cabral V, Accioli A, Bezerra M, Santarém E, Small I, Faccizoli A, Simões J, Ferreira C

Instituto Nacional do Câncer, Rio de Janeiro, Brazil

PD-007. Clinicopathological and pedigree differences in HNPCC Amsterdam I-positive families according to tumor microsatellite status. Familial colorectal cancer type x.

Perea J¹, Valle L¹, Carbonell P², Fernandez V¹, Benitez J¹, Urioste M¹

¹Familial Cancer Unit. Human Cancer Genetics Program. Spanish National Cancer Centre (CNIO). Madrid. SPAIN, ²Genetic Department. Virgen de la Arrixaca Hospital. Murcia. SPAIN.

PD-008. RAD001 and depot octreotide in advanced low-grade carcinoid and pancreatic neuroendocrine tumors: Phase 2 study

Phan A, Chang D, Rashid A, Meric-Bernstam F, Yao J

MD Anderson Cancer Center, Houston, TX, United States

PD-009. Nordic randomised study comparing XELOX30 (capecitabine and short time infusion oxaliplatin) with XELOX30C (chronomodulated XELOX30) as first line therapy in patients with advanced colorectal cancer

Qvortrup C

Odense University Hospital, Odense, Denmark

PD-010. A new high-throughput serum-based pre-colonoscopy screening test for colorectal cancer

Ritchie S¹, Heath D¹, Krenitsky K², Ardlie K², Sylwestrowicz T³

¹Phenomenome Discoveries, Inc., Saskatoon, Canada, ²Genomics Collaborative (A SeraCare Lifesciences Company), ³St. Paul's Hospital Saskatoon and University of Saskatchewan

PD-011. Reversal of early stages of colorectal cancer with EGF-receptor related protein (ERRP)

Schmelz E², Xu H¹, Du J¹, Rishi A¹, Sarkar F², **Majumdar A¹**

¹Wayne State University, ²Wayne State University

PD-012. First-line bevacizumab plus infusional 5-FU/irinotecan in metastatic CRC: Initial data from the AVIRI trial

Sobrero A¹, Ackland S², Perez Carrion R³, Chiara S⁴, Clarke S⁵, Garcia Giron C⁶, Langer B⁷, Zurlo A⁷, Young S⁸

¹Cliniche Universitarie Convenzionate U.O. Oncologia Medical, Genova, Italy, ²Department of Medical Oncology, Newcastle Mater Misericordiae Hospital, Waratah, Australia, ³Centro Oncologico MD Anderson Internacional Espana, Madrid, Spain, ⁴Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy, ⁵Oncology Department, Sydney Cancer Center, Concord Australia, ⁶Dept. Medical Oncology, Hospital General Yag,e, Burgos, Spain, ⁷F. Hoffmann - La Roche, Basel, Switzerland, ⁸Northeastern Ontario Regional Cancer Centre, Sudbury, Canada

PD-013. REGATE: What happens to gastric cancer treatment in the real world?

Ter-Ovanesov M¹, Bang Y², Wu C³, Yalcin S⁴, Roth A⁵, Zalcborg J⁶, Soloviev V⁷, Oliveros R⁸, Yankin A⁹, Narvaez C¹⁰

¹Russian N.N. Blokhin Cancer Research Center, ²Seoul National University Hospital, ³Veterans General Hospital-Taipei, ⁴Hacettepe University, Institute of Oncology, ⁵Hôpital Cantonal Universitaire de Genève (HUG), Onco-chirurgie, ⁶Peter MacCallum Cancer Centre, ⁷The Regional Oncological Clinical Dispensary, ⁸Instituto Nacional de Cancerología, ⁹District Oncological Dispensary, ¹⁰Clínica los Andes

PD-014. Hepatitis B viral load predicts survival of patients with hepatocellular carcinoma (HCC) undergoing systemic chemotherapy.

Yeo W, Chan P, Mo F, Lam K, Ho W, Koh J, Chan A

Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China